Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# International Myeloma Society

Multiple Myeloma Workshops

## Sitemaps

- [XML Sitemap](https://www.myelomasociety.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [IMS Connect - June 5, 2026](https://www.myelomasociety.org/ims-connect-june-5-2026/) - European panel publishes guidance on outpatient delivery of bispecifics Using a modified Delphi approach, a panel of European experts generated consensus recommendations on safe and effective outpatient step-up-dosing of bispecific antibody (bsAb) therapies for patients with multiple myeloma (MM). The report, published in the European Journal of Haematology, also provides guidance on care transition from academic

## Pages

- [Home](https://www.myelomasociety.org/)
- [IMS News Room](https://www.myelomasociety.org/ims-news-room/) - IMS 2026 Media Briefing-The State of Multiple Myeloma Cure Press Releases and Statements International Myeloma Society: ASCO and EHA Signal a Pivotal Moment in Multiple Myeloma Research - June 10, 2026 International Myeloma to Convene Global Experts in Warsaw for 4th Annual Workshop on Genomics - June 2, 2026 International Myeloma Society Launches National Webinar
- [IMS Connect](https://www.myelomasociety.org/ims-connect/) - IMS Connect IMS Connect is a weekly roundup of news in myeloma, which is distributed every Friday. Previous issues can be found here: July 3, 2026 June 26, 2026 June 19, 2026 June 12, 2026 June 5, 2026 May 29, 2026 May 22, 2026 May 15, 2026 May 8, 2026 May 1, 2026 April 24,
- [IMS Journal](https://www.myelomasociety.org/membership/ims-journal/)
- [IMS Connect - July 3, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-july-3-2026/) - Teclistamab-daratumumab combination wins CHMP backing The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion on extending the indication for teclistamab, combined with subcutaneous daratumumab, for treating patients with relapsed/refractory multiple myeloma (RRMM) as early as first relapse. The opinion was supported by the 83.4% reduction in the risk
- [IMS Connect - June 26, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-june-26-2026/) - Subcutaneous isatuximab delivery via on-body injector approved in Europe and Japan The European Commission and the Ministry of Health, Labor, and Welfare in Japan have approved subcutaneous isatuximab, delivered through an on-body injector, in combination with standard-of-care (SoC) myeloma therapies across all existing indications of isatuximab. The approval was supported by data from the phase 3 IRAKLIA study. UK’s NICE approves
- [IMS Connect - June 19, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-june-19-2026/) - Talquetamab-daratumumab combinations improve outcomes in RRMM In the MonumenTAL-3 study, talquetamab in combination with either daratumumab (Dara)-pomalidomide or Dara alone yielded improved progression-free survival (PFS), compared with Dara-pomalidomide-dexamethasone, in patients with relapsed or refractory multiple myeloma (RRMM) following ≥1 prior line of therapy, according to the report published in the New England Journal of Medicine. Novel
- [A statement from IMS President, Philippe Moreau, after the IMS Myeloma Cure Summit: Definitions, Metrics, and Milestones](https://www.myelomasociety.org/ims-news-room/a-statement-from-ims-president-philippe-moreau-after-the-ims-myeloma-cure-summit-definitions-metrics-and-milestones/) - A statement from IMS President, Philippe Moreau, after the IMS Myeloma Cure Summit: Definitions, Metrics, and Milestones “For many years, multiple myeloma has been described as treatable but not curable. Today, scientific advances have brought us closer to defining what cure means. The depth and durability of responses we are now seeing, along with major
- [International Myeloma Society Convenes Global Cure Summit to Chart the Scientific Path to a Myeloma Cure](https://www.myelomasociety.org/ims-news-room/international-myeloma-society-convenes-global-cure-summit-to-chart-the-scientific-path-to-a-myeloma-cure/) - International Myeloma Society Convenes Global Cure Summit to Chart the Scientific Path to a Myeloma Cure World’s leading myeloma experts gather Feb. 20–21 in Miami to examine long-term outcomes and assess whether long-lasting remission can truly signal cure; free global streaming available Miami, FL (January 22, 2026) — The International Myeloma Society (IMS) will convene
- [International Myeloma Society: ASCO and EHA Signal a Pivotal Moment in Multiple Myeloma Research](https://www.myelomasociety.org/ims-news-room/international-myeloma-society-asco-and-eha-signal-a-pivotal-moment-in-multiple-myeloma-research/) - International Myeloma Society: ASCO and EHA Signal a Pivotal Moment in Multiple Myeloma Research As breakthrough data continue to reshape the field, researchers are working to define what cure means in myeloma, and how earlier intervention, treatment sequencing, and deeper responses could help more patients reach that goal. Statement from Dr. Shaji Kumar, MD, Vice
- [IMS Connect - June 12, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-june-12-2026/) - US Panel of experts publishes myeloma treatment recommendations Using a modified Delphi approach, a panel of 16 US multiple myeloma (MM) experts generated consensus recommendations for MM management across the disease spectrum. The corresponding report was published in the American Journal of Hematology. CELMoD combination in the spotlight at EHA 2026 Late-Breaking Abstract Session The phase 3
- [IMS Connect - June 5, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-june-5-2026/) - European panel publishes guidance on outpatient delivery of bispecifics Using a modified Delphi approach, a panel of European experts generated consensus recommendations on safe and effective outpatient step-up-dosing of bispecific antibody (bsAb) therapies for patients with multiple myeloma (MM). The report, published in the European Journal of Haematology, also provides guidance on care transition from academic
- [IMS Connect - May 29, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-may-29-2026/) - ASCO publishes Living Guidelines for MM treatment The American Society of Clinical Oncology (ASCO) published Living Guidelines outlining recommendations for multiple myeloma (MM) treatment. The ASCO guidelines were published online ahead of the print issue of the Journal of Clinical Oncology on May 20, 2026. First dose of in vivo MM CAR-T therapy administered in the United States The
- [IMS Connect - May 22, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-may-22-2026/) - European expert panel publishes consensus on pre–CAR-T bridging therapy While bridging therapy is used for most patients with multiple myeloma (MM) who receive CAR-T therapy, especially to reduce tumor burden during the CAR-T manufacturing period, optimal bridging regimens require individualization. A panel of European MM experts published a consensus report in Bone Marrow Transplantation outlining its clinical
- [IMS Connect - November 28, 2025](https://www.myelomasociety.org/ims-connect/ims-connect-november-28-2025/) - UK’s NICE recommends talquetamab for use across England and Wales Talquetamab recommended by NICE for relapsed and refractory multiple myeloma Discover Pharma) “The National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending talquetamab for use in the NHS across England and Wales.” Talquetamab, a CD3- and GPRC5D-targeted bispecific antibody, was
- [IMS Connect - November 21, 2025](https://www.myelomasociety.org/ims-connect/ims-connect-november-21-2025/) - High-risk smoldering myeloma therapy gains US FDA approval The US FDA approved daratumumab as monotherapy for high-risk smoldering multiple myeloma (SMM) on November 6, 2025. The approval was based on the significantly lower risk of progression to active myeloma or death and higher overall survival with daratumumab, compared to active monitoring, in the phase 3 AQUILA trial. Daratumumab was
- [IMS Connect - November 14, 2025](https://www.myelomasociety.org/ims-connect/ims-connect-november-14-2025/) - FDA (re)approves belantamab mafodotin for relapsed/refractory multiple myeloma Cancer Drug Pulled From Market Regains FDA Approval (MedPage Today) “A B-cell maturation antigen (BCMA)-targeted agent, belantamab mafodotin is now indicated in combination with bortezomib (Velcade) and dexamethasone (BVd) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least two prior
- [IMS Connect - May 8, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-may-8-2026/) - Early relapse portends poor prognosis regardless of baseline risk Functional high-risk (FHR) multiple myeloma (MM)—defined as relapse within 12 months of initial therapy or stem cell transplant—is associated with poor outcomes. In a retrospective analysis of the CoMMpass dataset published in Cancer Medicine, patients with FHR had similar overall survival regardless of baseline risk. IMS’ 4th Annual Genomics Workshop (July
- [IMS Connect - May 1, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-may-1-2026/) - Cilta-cel yields universal MRD-negativity, prevents progression in SMM According to data from the phase 2 CAR-PRISM trial presented at the 2026 American Association of Cancer Research Annual Meeting, a single infusion of ciltacabtagene autoleucel, without induction or bridging therapy, resulted in minimal residual disease-negativity in all 20 patients with high-risk smoldering multiple myeloma. None of the
- [IMS Connect - March 6, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-march-6-2026/) - Proteasome inhibition can restore BCMA expression, anti-BCMA CAR T-cell activity BCMA loss on multiple myeloma (MM) cells is a resistance mechanism that contributes to relapse following anti-BCMA CAR-T therapy. Plasma membrane-associated BCMA is degraded via the ubiquitin-proteasome system, according to a report in Blood. Blocking BCMA degradation, via treatment with the proteasome inhibitor carfilzomib, not only
- [IMS Connect - March 27, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-march-27-2026/) - Stem cell boost improves hematologic recovery after real-world CAR-T therapy Cytopenias are common in CAR-T therapy recipients with myeloma, often occurring within 30 days and persisting for 30–90 days after CAR-T infusion. In a retrospective multicenter real-world study, published in Blood Cancer Journal, autologous stem cell boost (SCB) improved hematologic recovery, as indicated by higher median
- [IMS Connect - March 20, 2026](https://www.myelomasociety.org/ims-connect/march-20-2026/) - Application submitted for EU approval of teclistamab monotherapy at first relapse A Type II variation application has been submitted to the European Medicines Agency seeking approval of teclistamab for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy, according to a press release. The application is supported by topline data from
- [IMS Connect - March 13, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-march-13-2026/) - Teclistamab-daratumumab combination approved by US FDA The combination of teclistamab and daratumumab was approved by the US Food and Drug Administration (FDA) for treating patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior line of therapy. Based on data from the phase 3 MajesTEC-3 trial, this is the third approval under the new Commissioner’s National
- [IMS Connect - January 9, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-january-9-2026/) - Standardized definitions for transplant-ineligibility in myeloma are needed Autologous stem cell transplantation has remained a standard-of-care in the newly diagnosed multiple myeloma (NDMM) setting for several decades, even as the role of transplant in MM care continues to evolve with the introduction of highly efficacious new therapies. A systematic review published in the British Journal of
- [IMS Connect - January 30, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-january-30-2026/) - IMS/IMWG definition of high-risk myeloma validated in over 6,500 newly diagnosed patients The IMS-IMWG consensus genomic definition for high-risk multiple myeloma (HRMM), based on the 2023 IMS Genomic Meeting, was published in the Journal of Clinical Oncology in July 2025. Researchers in France validated the HRMM definition in a contemporary cohort of 6,528 newly diagnosed patients
- [IMS Connect - January 23, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-january-23-2026/) - All-oral CELMoD-based triplet demonstrates clinical activity in relapsed myeloma The combination of iberdomide, an oral cereblon E3 ligase modulator, with cyclophosphamide and dexamethasone demonstrated efficacy in patients with relapsed/refractory multiple myeloma (MM) who had received two to four previous lines of therapy. These findings, from the phase 2 ICON trial, were reported in The Lancet Haematology.
- [IMS Connect - January 2, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-january-2-2026/) - AI-driven retinal biomarkers demonstrate promise in predicting 10-year myeloma risk A study reported in the European Journal of Cancer outlined the predictive performance of RetHemo, an explainable artificial intelligence (AI) model for predicting the future risk of lymphoma, leukemia, and multiple myeloma (MM) using retinal imaging data. RetHemo, trained on pre-diagnosis fundus scans from a cohort with
- [IMS Connect - January 16, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-january-16-2026/) - Single-cell Immune Atlas may enable prediction of MM recurrence risk Dysregulation of the interactions between myeloma cells and the bone marrow microenvironment plays a key role in the pathogenesis and progression of myeloma. Leveraging single-cell RNA-sequencing-based profiling of almost 1.4 million cells from the bone marrow of 337 patients with newly diagnosed myeloma, researchers assembled
- [IMS Connect - February 6, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-february-6-2026/) - Daratumumab quadruplet indication expanded to include transplant-ineligible MM Daratumumab, combined with bortezomib, lenalidomide, and dexamethasone (Dara-VRd), was approved by the US Food and Drug Administration (FDA) for treating transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), based on CEPHEUS findings. A post hoc analysis of CEPHEUS presented at the 2025 IMS Annual Meeting established the
- [IMS Connect - February 27, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-february-27-2026/) - FDA grants Priority Review to iberdomide combination for RRMM The US FDA has granted Priority Review for a New Drug Application (NDA) for iberdomide in combination with daratumumab and dexamethasone, as a treatment for patients with relapsed/refractory multiple myeloma (RRMM). The iberdomide-daratumumab-dexamethasone combination was evaluated in the phase 3 EXCALIBER-RRMM trial. IMS-IMWG high-risk criteria predict
- [IMS Connect - February 20, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-february-20-2026/) - IMS-IMWG high-risk myeloma definition outperforms older high-risk criteria The IMS-IMWG consensus genomic definition for high-risk multiple myeloma (HRMM) performed better at predicting poor survival outcomes in patients who received quadruplet-based induction and hematopoietic stem cell transplant, compared with an older definition of HRMM based on the presence of t(4;14), t(14;16), or del(17p). In a report published in
- [IMS Connect - February 13, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-february-13/) - New commercial next-generation flow-based MRD test launched A new commercial next-generation flow (NGF)-based minimal residual disease (MRD) test for multiple myeloma (MM) was launched by Quest Diagnostics. The test is expected to be available at about 7,000 Quest locations. The launch comes on the heels of the recent Draft Guidance issued by the U.S. FDA on the use of
- [IMS Connect - December 5, 2025](https://www.myelomasociety.org/ims-connect/ims-connect-december-5-2025/) - Use of real-world data/evidence in MM drug approvals The role of real-world data/evidence (RWD/E) in regulatory applications was a key topic of discussion at the 2024 IMS-European Medicines Agency (EMA) Joint Meeting. An editorial published in Blood Cancer Journal digs deeper into this topic. A Special Interest Session at the 2025 American Society of Hematology (ASH) Annual
- [IMS Connect - December 19, 2025](https://www.myelomasociety.org/ims-connect/ims-connect-december-19-2025/) - Teclistamab-daratumumab combination granted a national priority voucher in RRMM The U.S. Food and Drug Administration (FDA) proactively awarded a national priority voucher for the combination of teclistamab and daratumumab for relapsed/refractory multiple myeloma (RRMM), based on the “outstanding results” from the phase 3 MajesTEC-3 trial. The FDA Commissioner’s National Priority Voucher is a pilot program
- [IMS Connect - December 12, 2025](https://www.myelomasociety.org/ims-connect/ims-connect-december-12-2025/) - Evolving methods and role for MRD detection in multiple myeloma Minimal residual disease (MRD) detection methods and the role of MRD as a prognostic indicator and surrogate for survival outcomes in myeloma continue to evolve. A perspective article published in Leukemia explores MRD assessment in MM. The potential for non-bone marrow sampling-based MRD testing is an active
- [IMS Connect - April 3, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-april-3-2026/) - New methods for administering anti-CD38 monoclonal antibodies gain EMA nods The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued an approval/positive opinion on new, patient-friendlier/more convenient methods for administering anti-CD38 monoclonal antibody therapies. EMA approved subcutaneous daratumumab for administration by a patient or caregiver, from the fifth dose onward, after
- [IMS Connect - April 24, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-april-24-2026/) - Belantamab combination regimen gains nods from UK’s NICE and China’s NMPA United Kingdom’s National Institute for Health and Care Excellence (NICE) issued a draft guidance recommending belantamab mafodotin, in combination with bortezomib and dexamethasone (BVd), for treating patients with multiple myeloma (RRMM) who have received ≥1 prior therapy. NICE is expected to publish the final guidance
- [IMS Connect - April 17, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-april-17-2026/) - Review weighs evidence for and implications of isatuximab on-body injector The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently issued a positive opinion supporting approval of the novel on-body injector (OBI) for subcutaneous isatuximab. In a report published in Expert Opinion on Drug Delivery, experts review the evidence for the isatuximab
- [IMS Connect - April 10, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-april-10/) - Allogeneic anti-BCMA CAR-T therapy granted FDA RMAT designation Currently, all approved CAR-T therapies, including those for treating patients with multiple myeloma (MM), are autologous. An allogeneic anti-BCMA CAR-T therapy for MM — CB-011 — has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US FDA. CB-011 yielded deep and durable responses in high-risk patients with
- [IMS Connect - May 15, 2026](https://www.myelomasociety.org/ims-connect/ims-connect-may-15-2026/) - Pan-Pacific MM Working Group publishes MRD-adapted treatment guidelines Minimal residual disease (MRD) is prognostic of progression-free and overall survival in multiple myeloma (MM). The Pan-Pacific Multiple Myeloma Working Group has published guidelines and consensus recommendations in Clinical Hematology International outlining the optimal approach to incorporating MRD evaluation in clinical decision-making. Dexamethasone-free regimen demonstrates potential in elderly frail
- [International Myeloma Society Opens Abstract Submissions for 23rd Annual Meeting](https://www.myelomasociety.org/ims-news-room/international-myeloma-society-opens-abstract-submissions-for-23rd-annual-meeting/) - International Myeloma Society Opens Abstract Submissions for 23rd Annual Meeting Abstract submissions and registration now open for 23rd IMS Annual Meeting, taking place September 23-26, 2026 (Glasgow, Scotland) – March 27, 2026 – The International Myeloma Society (IMS) today announced that abstract submissions and registration are now open for the 23rd IMS Annual Meeting, taking
- [International Myeloma Society Launches National Webinar Series to Support Community Use of Emerging Immunotherapies in Multiple Myeloma](https://www.myelomasociety.org/ims-news-room/international-myeloma-society-launches-national-webinar-series-to-support-community-use-of-emerging-immunotherapies-in-multiple-myeloma/) - International Myeloma Society Launches National Webinar Series to Support Community Use of Emerging Immunotherapies in Multiple Myeloma Six-part educational initiative aims to help community oncologists navigate the growing complexity of CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates The International Myeloma Society (IMS) is launching its new U.S. Community Webinar Series, “IMS Community Webinar Series:
- [International Myeloma to Convene Global Experts in Warsaw for 4th Annual Workshop on Genomics](https://www.myelomasociety.org/ims-news-room/international-myeloma-to-convene-global-experts-in-warsaw-for-4th-annual-workshop-on-genomics/) - International Myeloma to Convene Global Experts in Warsaw for 4th Annual Workshop on Genomics Leading researchers and clinicians will focus on defining and advancing treatment strategies for functional and ultra-high-risk multiple myeloma (Boston, MA) – June 2, 2026 – The International Myeloma Society (IMS) will convene leading international researchers and clinicians in Warsaw, Poland on
- [](https://www.myelomasociety.org/19814-2/)
- [Subscribe to IMS](https://www.myelomasociety.org/subscribe-to-ims/) - Subscribe * indicates required Email Address * First Name Last Name
- [GLO @IMS](https://www.myelomasociety.org/glo-ims/)
- [Meeting Materials](https://www.myelomasociety.org/meeting-materials/) - Meeting Materials A benefit of IMS membership is access to meeting materials from the IMS Annual Meeting, other events sponsored by IMS, and other major myeloma meetings. To access slides and other materials from the listed meetings, click the links below. West Coast Webinar on NDMM and RRMM - April 2026 East Coast Webinar on
- [Membership Information](https://www.myelomasociety.org/about-us/member-details/membership-information/)
- [About Us](https://www.myelomasociety.org/about-us/)
- [Renew IMS Membership](https://www.myelomasociety.org/renew-membership-3/) - hello
- [Member Details/Become a Member](https://www.myelomasociety.org/about-us/member-details/) - Membership Information IMS aims to promote research, education, clinical studies, and workshops to improve prevention, diagnosis, prognosis, and treatment of multiple myeloma and related disorders for patients worldwide. The International Myeloma Society is an organization that fosters scientific exchange and will be responsible for the final selection of the International Myeloma Workshops. Membership Benefits You
- [Donate To IMS](https://www.myelomasociety.org/donate-to-ims/)
- [Privacy Policy](https://www.myelomasociety.org/privacy-policy/) - Terms and conditions Web privacy policy We take your privacy seriously, and we want you to know how we collect, use, share and protect your information. What information we collect We respect the right to privacy of all visitors to the International Myeloma Society site. We do not collect information that would personally identify you
- [Renew](https://www.myelomasociety.org/renew/) - Memberships are nonrefundable.
- [Donate](https://www.myelomasociety.org/donate/)
- [IMS Career Development Award](https://www.myelomasociety.org/grants/ims-career-development-award/) - IMS Awards for Exemplary Abstracts Through the Awards for Exemplary Abstracts, the International Myeloma Society provides travel grants to young myeloma researchers to assist with expenses relating to their participation at the 17th International Myeloma Workshop. The IMS Board will decide, according to the scores of the abstracts and the quality of presentation, which investigators
- [International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Research Grant](https://www.myelomasociety.org/grants/international-myeloma-society-ims-and-paula-and-rodger-riney-foundation-translational-research-grant/) - IMS Awards for Exemplary Abstracts Through the Awards for Exemplary Abstracts, the International Myeloma Society provides travel grants to young myeloma researchers to assist with expenses relating to their participation at the 17th International Myeloma Workshop. The IMS Board will decide, according to the scores of the abstracts and the quality of presentation, which investigators
- [Ristretto test page](https://www.myelomasociety.org/ristretto-test-page-2/)
- [Officers](https://www.myelomasociety.org/about-us/officers/)
- [Education](https://www.myelomasociety.org/education/) - One of the most important goals of IMS is to provide clinically focused education to practicing oncologists worldwide. The IMS accomplishes this mission by providing educational forums in the form of workshops conducted around the globe. The goal for the Educational Workshop is to share with local hematologists state-of-the-art methods in diagnosis, monitoring and treatment
- [Past Events](https://www.myelomasociety.org/past-events/)
- [Publications](https://www.myelomasociety.org/publications/)
- [Ken Anderson Basic and Translational Research Award](https://www.myelomasociety.org/awards/ken-anderson-young-investigator-award/) - IMS Awards for Exemplary Abstracts Through the Awards for Exemplary Abstracts, the International Myeloma Society provides travel grants to young myeloma researchers to assist with expenses relating to their participation at the 17th International Myeloma Workshop. The IMS Board will decide, according to the scores of the abstracts and the quality of presentation, which investigators
- [Bart Barlogie Clinical Investigator Award](https://www.myelomasociety.org/awards/bart-barlogie-young-investigator-award/) - IMS Awards for Exemplary Abstracts Through the Awards for Exemplary Abstracts, the International Myeloma Society provides travel grants to young myeloma researchers to assist with expenses relating to their participation at the 17th International Myeloma Workshop. The IMS Board will decide, according to the scores of the abstracts and the quality of presentation, which investigators
- [Waldenström Lifetime Achievement Award](https://www.myelomasociety.org/awards/waldenstrom-award/) - IMS Awards for Exemplary Abstracts Through the Awards for Exemplary Abstracts, the International Myeloma Society provides travel grants to young myeloma researchers to assist with expenses relating to their participation at the 17th International Myeloma Workshop. The IMS Board will decide, according to the scores of the abstracts and the quality of presentation, which investigators
- [Young Investigator Award](https://www.myelomasociety.org/grants/ims-awards-for-exemplary-abstracts/) - IMS Awards for Exemplary Abstracts Through the Awards for Exemplary Abstracts, the International Myeloma Society provides travel grants to young myeloma researchers to assist with expenses relating to their participation at the 17th International Myeloma Workshop. The IMS Board will decide, according to the scores of the abstracts and the quality of presentation, which investigators
- [IMS Educational Workshop in Marrakech](https://www.myelomasociety.org/ims-educational-workshop-in-marrakech/)
- [](https://www.myelomasociety.org/19144-2/)
- [Contact](https://www.myelomasociety.org/contact/)
- [IMS Educational Workshop Johannesburg](https://www.myelomasociety.org/ims-educational-workshop-johannesburg/)
- [Events](https://www.myelomasociety.org/events/)
- [IMSound](https://www.myelomasociety.org/imsound/)
- [Grants](https://www.myelomasociety.org/grants/)
- [TMAP](https://www.myelomasociety.org/advocacy/tmap/) - Coming soon! - TMAP The IMS remains focused on providing support and educational tools to help oncologists and hematologists world-wide with treatment decisions for myeloma patients. Therapies for multiple myeloma have evolved very rapidly over the past several years with a significant improvement in outcomes. However, access and availability of drugs remain variable and dictated
- [Awards](https://www.myelomasociety.org/awards/)
- [Members Directory](https://www.myelomasociety.org/membership/directory/)
- [Subcommittees](https://www.myelomasociety.org/about-us/subcommittees/) - Subcommittees Each of the coordinators of the different subcommittees will take the lead in order to activate the corresponding committee and to define and implement specific actions. Financial Committee Kenneth Anderson, Sagar Lonial Shaji Kumar, Jesús San Miguel, Tom Martin, Philippe Moreau Mission Statement: Recommend financial policies, goals, and budgets that support the mission, values, and strategic
- [Advocacy](https://www.myelomasociety.org/advocacy/)
- [Career Development Award](https://www.myelomasociety.org/career-development-award/)
- [Translational Research Award](https://www.myelomasociety.org/translational-research-award/)
- [Member Area](https://www.myelomasociety.org/membership/)
- [IMS Journal General Information](https://www.myelomasociety.org/ims-journal-general-information/)
- [](https://www.myelomasociety.org/4466-2/) - Translational Research Award Application 2023
- [](https://www.myelomasociety.org/4307-2/) - Career Development Award Application 2023
- [Verification](https://www.myelomasociety.org/6500-2/) - Thank you for submitting your verification letter to the IMS. Our staff will contact you to confirm your status as a member-in-training of the International Myeloma Society.
- [Welcome](https://www.myelomasociety.org/membership/welcome/)
- [Member Details](https://www.myelomasociety.org/membership/welcome/member-details/)
- [News](https://www.myelomasociety.org/news/)
- [IMW Meeting Materials 2021](https://www.myelomasociety.org/imw-meeting-materials-2021/) - IMW Meeting Materials 2021 IMW 2021 Program Wednesday, September, 2021 Precursor Conditions Genomic evolution germinal B cell to MGUS/SMM/MM - Brian Walker Role of the immune Microenvironment in the journey to MGUS/SMM/MM - Madhav Dhodapkar Molecular Timing of Initiation - Niels Weinhold Risk factors for MGUS/SMM progression - Vincent Rajkumar Management of Smoldering Myeloma -
- [Targeting the Undruggable in Multiple Myeloma](https://www.myelomasociety.org/targeting-the-undruggable-in-multiple-myeloma/) - Targeting the Undruggable in Multiple Myeloma Mariateresa Fulciniti, PhD Dana-Farber Cancer Institute Cell identity is controlled by the action of a small number of master transcription factors (TFs) that recognize and bind specific sequences in the genome and thereby regulate specific gene expression programs. Tumor cells commonly have deregulated gene expression programs, yielding the concept
- [Publication List](https://www.myelomasociety.org/publication-list/) - Clinical Research in Multiple Myeloma: Recent literature – Editors’ picks Compiled by Efstathios Kastritis, MD National and Kapodistrian University of Athens Newly diagnosed MM – Transplant eligible Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Roussel M, Lauwers-Cances V, Wuilleme S, Belhadj K, Manier S, Garderet
- [Basic and translational Myeloma Research: Recent literature- Editor’s picks](https://www.myelomasociety.org/basic-and-translational-myeloma-research-recent-literature-editors-picks/) - Basic and translational Myeloma Research: Recent literature- Editors' picks Compiled by Mariateresa Fulciniti, PhD Dana-Farber Cancer Institute Myeloma Genomics Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Oben B, Froyen G, Maclachlan KH, Leongamornlert D, Abascal F, Zheng-Lin B, Yellapantula V, Derkach A, Geerdens E, Diamond BT, Arijs I, Maes B, Vanhees K, Hultcrantz
- [Letter from the President](https://www.myelomasociety.org/letter-from-the-president/) - Dear IMS Members, Welcome to the First Newsletter from International Myeloma Society! Over the past year and a half, we have witnessed the world change. The impact of the COVID-19 pandemic and the losses incurred cannot be over-stated and will never be forgotten. Although it is a time of great tragedy, we have also watched
- [IMS and Riney Foundation](https://www.myelomasociety.org/ims-and-riney-foundation/) - Riney Foundation Funds Grants for Myeloma Research The Paula and Rodger Riney Foundation partnered with International Myeloma Society to further their mutual goals of supporting cutting-edge translational research and further careers of young basic and clinical researchers in myeloma. The goals of the Foundation and the society has been to promote interdisciplinary collaborations among colleagues
- [IMW 2021 Awardees](https://www.myelomasociety.org/imw-2021-awardees/) - CONGRATULATIONS TO THE IMS AWARDS RECIPIENTS Join us on Wednesday, September 8 at 14:30 for the formal recognition of all IMS award recipients in the Plenary Session Hall, Hall A. WALDENSTRÖM AWARD S. Vincent Rajkumar, MD Mayo Clinic Rochester, United States The Waldenström Award has been given
- [Updates in the treatment of patients with high-risk myeloma  ](https://www.myelomasociety.org/updates-in-the-treatment-of-patients-with-high-risk-myeloma/) - Updates in the treatment of patients with high-risk myeloma Efstathios Kastritis, MD National and Kapodistrian University of Athens Several studies evaluated new combinations for the treatment of myeloma patients who present with high risk characteristics (advanced ISS and high risk cytogenetics) and who may have quiet poor prognosis. Prof M. Kaiser presented at both ASCO
- [IMW 2021 Welcome](https://www.myelomasociety.org/news/imw-2021-welcome/) - IMW 2021 Welcome Dear Colleagues, I am pleased to invite you on behalf of the president of the International Myeloma Society, Nikhil Munshi, and of the local organizers Hermann Einsele, Hartmut Goldschmidt and Roman Hajek to attend the forthcoming 18th Multiple Myeloma Workshop in Vienna, Austria, September 8-11, 2021. The meeting provides an extensive overview of the
- [MULTIPLE MYELOMA BASIC & TRANSLATIONAL RESEARCH SPOTLIGHT](https://www.myelomasociety.org/multiple-myeloma-basic-translational-research-spotlight/) - Myeloma Research Spotlight Turning Cold into Hot Myeloma Mariateresa Fulciniti, PhD Recent studies have shown how anticancer drugs mediate their activity not only by direct cytostatic or cytotoxic effects but also stressing cancer cells in such a way that they become recognizable to the immune system, read more... Targeting the Undruggable in Multiple Myeloma Mariateresa Fulciniti,
- [Activation of immunogenic cell death (ICD) and therapeutic efficacy in MM](https://www.myelomasociety.org/news/activation-of-immunogenic-cell-death-icd-and-therapeutic-efficacy-in-mm/) - Turning Cold into Hot Myeloma Mariateresa Fulciniti, PhD Dana-Farber Cancer Institute Anticancer drugs mediate their activity not only by direct cytostatic or cytotoxic effects but also stressing cancer cells in such a way that they become recognizable to the immune system, a process known as “immunogenic cell death” (ICD) (https://pubmed.ncbi.nlm.nih.gov/27748397/). A recent study, led by Ken Anderson from Dana-Farber
- [Treatment of new diagnosed myeloma patients](https://www.myelomasociety.org/treatment-of-new-diagnosed-myeloma-patients/) - Treatment of new diagnosed myeloma patients Efstathios Kastritis, MD National and Kapodistrian University of Athens Significant updates were presented in ASCO and EHA for the treatment of patients newly diagnosed disease. In the late breaking abstract session, Prof. T. Facon presented the results on overall survival from the MAIA study comparing Dara-Rd vs Rd in
- [EHA/ASH 2021 Update](https://www.myelomasociety.org/eha-ash-2021-update/) - Myeloma Updates from ASCO and EHA 2021 In the recent ASCO and EHA meetings several important abstracts were presented regarding the treatment and management of multiple myeloma. Treatment of new diagnosed myeloma patients Updates in the treatment of patients with high risk myeloma Evaluation of response to therapy and the critical role of MRD and
- [T-cell redirecting therapies for multiple myeloma treatment](https://www.myelomasociety.org/t-cell-redirecting-therapies-for-multiple-myeloma-treatment/) - T-cell redirecting therapies for multiple myeloma treatment Niels van de Donk, MD, PhD VU University Medical Center Triple-class refractory MM patients have a poor outcome and have an unmet medical need for new effective therapies. The LocoMMotion study provides real-world data on outcomes in triple-class exposed MM patients who receive standard-of-care therapies. The first analysis
- [Evaluation of response to therapy and the critical role of MRD and new approaches to imaging](https://www.myelomasociety.org/evaluation-of-response-to-therapy-and-the-critical-role-of-mrd-and-new-approaches-to-imaging/) - Evaluation of response to therapy and the critical role of MRD and new approaches to imaging Efstathios Kastritis, MD National and Kapodistrian University of Athens Several abstract confirmed the critical prognostic value of evaluation of MRD in newly diagnosed patients with myeloma treated with or without ASCT. Also, the potential of mass spectrometry for the
- [Treatment of patients with relapsed or refractory myeloma](https://www.myelomasociety.org/treatment-of-patients-with-relapsed-or-refractory-myeloma/) - Treatment of patients with relapsed or refractory myeloma Efstathios Kastritis, MD National and Kapodistrian University of Athens Several presentations provided updated data and new information of new combinations for the treatment of patients with relapsed of refractory myeloma. The ICARIA study compared isatuximab plus pomalidomide with dexamethasone vs pomalidomide with dexamethasone in patients with relapsed/refractory
- [Case Corner](https://www.myelomasociety.org/case-corner/) - In each issue, the IMS newsletter will feature a new case. To read the results of this issue's case, please come back for the next issue! Do you have an idea for a case for a future issue? If so, send it to us!
- [Vaccination against SARS-CoV-2: Suboptimal Response in Myeloma Patients Under Therapy](https://www.myelomasociety.org/vaccination-against-sars-cov-2-suboptimal-response-in-myeloma-patients-under-therapy/) - Vaccination against SARS-CoV-2: Suboptimal Response in Myeloma Patients Under Therapy Evangelos Terpos, MD, PhD; Professor of Hematology National and Kapodistrian University of Athens, School of Medicine, Athens, Greece Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies, including CLL and MM. In a very recent study published in the
- [COVID-19 Increases Morbidity and Mortality in Myeloma Patients: One Third of Hospitalized Myeloma Patients Die Because of SARS-CoV-2](https://www.myelomasociety.org/covid-19-increases-morbidity-and-mortality-in-myeloma-patients-one-third-of-hospitalized-myeloma-patients-die-because-of-sars-cov-2/) - COVID-19 Increases Morbidity and Mortality in Myeloma Patients: One Third of Hospitalized Myeloma Patients Die Because of SARS-CoV-2 Evangelos Terpos, MD, PhD; Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece COVID-19 pandemic has influenced the clinical care of multiple myeloma (MM) patients. The International Myeloma Society has studied the
- [APOLLO Study](https://www.myelomasociety.org/apollo-study/) - Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial Evangelos Terpos, MD, PhD Department of Clinical Therapeutics, Plasma Cell Dyscrasias Unit, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece The second is the APOLLO study that was published in
- [Labs from Around the World](https://www.myelomasociety.org/labs-from-around-the-world/) - Research Lab Spotlight: A look inside Dr. Lugui Qiu's Lab Dr. Qiu’s Myeloma Research Laboratory was founded in 2007 at The National Key Lab of Experimental Hematology in the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The main emphasis of Dr. Qiu’s research team is
- [COVID Corner](https://www.myelomasociety.org/covid-corner/) - COVID Corner COVID-19 Increases Morbidity and Mortality in Myeloma Patients: One Third of Hospitalized Myeloma Patients Die Because of SARS-CoV-2 Vaccination against SARS-CoV-2: Suboptimal Response in Myeloma Patients Under Therapy Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic
- [2nd Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/events/2nd-immune-effector-cell-therapies-in-multiple-myeloma-workshop/) - Building upon the success of the inaugural workshop held in April 2019, the International Myeloma Society is happy to host the 2nd Immune Effector Cell Therapies in Multiple Myeloma Workshop to discuss various immune-based therapies in myeloma including CART cell clinical data and promising preclinical leads, review the latest correlative analyses exploring predictors of response
- [AL Amyloidosis](https://www.myelomasociety.org/al-amyloidosis/) - AL Amyloidosis Efstathios Kastritis, MD National and Kapodistrian University of Athens Updated results for the treatment of AL amyloidosis were also presented in both meetings. In the ANDROMEDA trial, the combination of subcutaneous daratumumab with VCD plus daratumumab maintenance was compared to VCD alone in newly diagnosed patients with AL amyloidosis. In the update of
- [Quiz September Issue](https://www.myelomasociety.org/quiz-september-issue/) - Learn the answer to this month's quiz in our next issue! Do you have an idea for a case for a future issue? If so, send it to us!
- [Photo Contest](https://www.myelomasociety.org/photo-contest/) - Photo Contest Penguins at Play Antarctica Taken by: S. Vincent Rajkumar Camera: Canon EOS Mark III f22 1/160 ISO200 Are you an amateur photographer? The IMS Post is inviting our readers to submit photos for each issue! If you have a photo, please send it to us and it will be eligible to
- [Clinical Spotlight](https://www.myelomasociety.org/clinical-spotlight/) - Clinical Spotlights in the Treatment of Relapsed/Refractory Myeloma: Novel Publications with anti-CD38-based Combinations Evangelos Terpos, MD, PhD Department of Clinical Therapeutics, Plasma Cell Dyscrasias Unit, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece During the last 3 months, the results of two important phase-3 studies, using anti-CD38 monoclonal antibodies for the
- [IKEMA study](https://www.myelomasociety.org/ikema-study/) - Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial Evangelos Terpos, MD, PhD Department of Clinical Therapeutics, Plasma Cell Dyscrasias Unit, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece The Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA) Study, a multicentre, open-label, randomised
- [Life outside of Myeloma: Joan Blade](https://www.myelomasociety.org/life-outside-of-myeloma-joan-blade/) - Life Outside of Myeloma: Joan Bladé's Champion Canaries Neils van de Donk MD, PhD, VU University Medical Center Dr. Joan Bladé was no stranger to raising animals when he bought his first pair of canaries from a local canary breeder as a hematology fellow. Having grown up on a farm in the small town of
- [Login](https://www.myelomasociety.org/login/)
- [Account](https://www.myelomasociety.org/membership/account/)
- [Thank You](https://www.myelomasociety.org/thank-you/) - Your subscription has been set up successfully.
- [Become a Member](https://www.myelomasociety.org/membership/become-a-member/)

## Memberships

- [Single Year Status - Low and Middle Income Countries](https://www.myelomasociety.org/register/single-year-status-low-and-middle-income-countries/)
- [Single Year Status - Member-in-Training](https://www.myelomasociety.org/register/single-year-status-member-in-training/)
- [Single Year Membership - Associate Member](https://www.myelomasociety.org/register/single-year-membership-associate-members/)
- [Single Year Membership - Resident, Emeritus and Fellows](https://www.myelomasociety.org/register/single-year-membership-resident-emeritus-and-fellows/)
- [Two Year Membership](https://www.myelomasociety.org/register/2-year-membership/)
- [Single Year Membership](https://www.myelomasociety.org/register/single-year-membership/)

## Groups

- [IMS Members](https://www.myelomasociety.org/plans/ims-members/)

## Awards

- [Improving Prognosis of Progression Risk in Multiple Myeloma Precursors through Single Cell Sequencing-Based Genomic and Immune Microenvironment Profiling](https://www.myelomasociety.org/award/improving-prognosis-of-progression-risk-in-multiple-myeloma-precursors-through-single-cell-sequencing-based-genomic-and-immune-microenvironment-profiling-2/) - The accurate stratification of multiple myeloma (MM) patients by progression risk, into Monoclonal Gammopathy of Undetermined Significance (MGUS) with lower disease burden of 1% progression to MM and Smoldering Myeloma (SMM) with a 10% risk of advancing to MM, remains an urgent clinical need. Basing this stratification on whole genome sequencing (WGS) combined with single
- [Functional screens on single-cell transcriptomes of genotypically-defined minimal residual disease cells to unravel specific vulnerabilities of treatment resistant multiple myeloma (FUTURE)](https://www.myelomasociety.org/award/functional-screens-on-single-cell-transcriptomes-of-genotypically-defined-minimal-residual-disease-cells-to-unravel-specific-vulnerabilities-of-treatment-resistant-multiple-myeloma-future/) - The research proposed in this grant stems from the hypothesis that phenotypic hierarchies between distinct clonal cells may explain MM ontogeny and relapse patterns, and that through innovative approaches this can be harnessed to provide better biomarkers of treatment response and vulnerabilities to eradicate residual cells. I propose an unbiased simultaneous analysis of B-cell receptor
- [Comprehensive genomic and immune characterization of response and resistance to daratumumab-based quadruplet induction therapy](https://www.myelomasociety.org/award/comprehensive-genomic-and-immune-characterization-of-response-and-resistance-to-daratumumab-based-quadruplet-induction-therapy/) - This study aims to comprehensively characterize the genomic and immune landscape of newly diagnosed multiple myeloma (NDMM) patients treated with daratumumab-based quadruplet induction therapy (dara-quads). Preliminary data suggests that standard prognostic scores are inadequate for predicting outcomes, necessitating the inclusion of complex genomic and immune features. Specific Aim 1 focuses on identifying genomic features associated
- [Targeting inter-organelle communication to arrest multiple myeloma](https://www.myelomasociety.org/award/targeting-inter-organelle-communication-to-arrest-multiple-myeloma/) - Multiple Myeloma (MM) is marked by the clonal expansion of abnormal plasma cells (PCs) in the bone marrow. It is the second most common hematologic malignancy, predominantly affecting the elderly, men, and Non-Hispanic Black individuals. While current treatments often induce remission, MM remains incurable, relapsing and causing chronic organ damage and high healthcare costs. Thus,
- [Investigating heme-induced effector CAR T cells for multiple myeloma therapy](https://www.myelomasociety.org/award/investigating-heme-induced-effector-car-t-cells-for-multiple-myeloma-therapy/) - Mitochondrial energetics and cellular metabolism play a central role in regulating T cell differentiation, fate and function. Heme (iron-protoporphyrin IX) is critical for maintaining mitochondrial electron transport chain (ETC) activity and oxidative phosphorylation (OXPHOS). Heme is taken up from the extrinsic environment in addition to being synthesized intracellularly. Our objective is to understand how heme
- [Comprehensive Exploration of Molecular Pathways and Biomarkers in Myeloma-Induced Bone Disease: A Multi-Omics Approach for Personalized Therapeutic Management](https://www.myelomasociety.org/award/comprehensive-exploration-of-molecular-pathways-and-biomarkers-in-myeloma-induced-bone-disease-a-multi-omics-approach-for-personalized-therapeutic-management/) - The overarching objective of this proposal is to decipher the intricate molecular pathways, underlying myeloma-induced bone disease (MBD), a critical aspect of multiple myeloma pathogenesis. Employing state-of-the-art imaging, genomic and proteomic analyses, the proposal seeks to unravel the complex interplay between myeloma cells and the bone microenvironment. The objective of the proposal is to establish
- [iMMagine](https://www.myelomasociety.org/award/immagine/) - We hypothesize that tumor-immune microenvironment and macroenvironment alterations shape MM progression and treatment resistance. The problem is that the current understanding of immune resilience vs loss of function in MM is limited and, because of it, there are no immune biomarkers ready for primetime use in laboratory diagnostics. The consequence of this problem is that
- [Dissect the mechanisms by which CST6N137D enhances the efficacy of CAR-T cell therapy in myeloma](https://www.myelomasociety.org/award/dissect-the-mechanisms-by-which-cst6n137d-enhances-the-efficacy-of-car-t-cell-therapy-in-myeloma/) - Our preliminary data demonstrate that CST6N137D prevents downmodulation of the CAR on the surface of CAR-T cells, maintains persistence of CAR-T cells in the body, and enhances therapeutic killing of MM cells by CAR-T cells. In this application, we will (1) determine whether CST6N137D suppresses lysosomal degradation, thereby preventing CAR downmodulation; and (2) determine the
- [Targeting Collagen-LAIR1 for Improving Multiple Myeloma Therapeutic Efficacy](https://www.myelomasociety.org/award/targeting-collagen-lair1-for-improving-multiple-myeloma-therapeutic-efficacy/) - The project aims to uncover how the bone marrow microenvironment allows tumor cells to survive treatment and cause relapse in multiple myeloma. Dormancy refers to a state in which residual tumor cells persist without net growth. The dormant cells evade both cytotoxic drugs and immune surveillance, later reactivating to drive relapse. A critical barrier to
- [SHIELD-MM - A modular multiplex shRNA platform to enhance functional persistence of academic anti-BCMA CAR-T cells (ARI0002h) in multiple myeloma.](https://www.myelomasociety.org/award/shield-mm-a-modular-multiplex-shrna-platform-to-enhance-functional-persistence-of-academic-anti-bcma-car-t-cells-ari0002h-in-multiple-myeloma/) - Anti-BCMA CAR-T cell therapies achieve deep responses in relapsed/refractory multiple myeloma, yet most patients eventually relapse, largely due to limited long-term persistence and progressive dysfunction of CAR-T cells under chronic tumor antigen exposure. SHIELD-MM addresses this critical limitation by developing a next-generation version of ARI0002h — an academic anti-BCMA CAR-T product authorized by the Spanish
- [Targeting TCF3 addiction in multiple myeloma](https://www.myelomasociety.org/award/targeting-tcf3-addiction-in-multiple-myeloma/) - Multiple myeloma remains an incurable malignancy, with most patients ultimately relapsing due to therapy-resistant disease. While the genetic landscape of multiple myeloma is highly heterogeneous, malignant plasma cells often converge on shared transcriptional dependencies that sustain tumor survival. Among these, the transcription factor TCF3 has emerged as a highly selective and previously unexplored vulnerability in
- [Exploiting translation control vulnerabilities imposed by antibody secretion in multiple myeloma](https://www.myelomasociety.org/award/exploiting-translation-control-vulnerabilities-imposed-by-antibody-secretion-in-multiple-myeloma/) - Our project investigates how malignant plasma cells cope with the stress associated with high antibody production. While current therapies already exploit the fragility of these cells by interfering with protein degradation systems, the mechanisms that sustain this intense protein production remain poorly understood. Our research focuses on a newly emerging layer of regulation that controls
- [Nanobody-based IL-18-armored BCMA/BAFF-R dual-CAR T Cells to Overcome Treatment Failure in Multiple Myeloma](https://www.myelomasociety.org/award/nanobody-based-il-18-armored-bcma-baff-r-dual-car-t-cells-to-overcome-treatment-failure-in-multiple-myeloma/) - We have recently evaluated IL-18-secreting dual-CAR T cells targeting BCMA and BAFF-R in a syngeneic mouse model of multiple myeloma as a comprehensive approach to simultaneously overcome multiple CAR T cell failure mechanisms. Engineered IL-18 secretion by BCMA and BAFF-R-targeting CAR T cells enabled elimination of antigen-low myeloma, stimulated macrophage killing of myeloma cells, activated
- [Defining the risk of clonal hematopoiesis and therapy-related myeloid neoplasms in multiple myeloma patients receiving ASCT and lenalidomide maintenance](https://www.myelomasociety.org/award/defining-the-risk-of-clonal-hematopoiesis-and-therapy-related-myeloid-neoplasms-in-multiple-myeloma-patients-receiving-asct-and-lenalidomide-maintenance/) - This project aims to determine whether DNA damage response–associated clonal hematopoiesis (DDR-CH) predicts therapy-related myeloid neoplasms in multiple myeloma patients receiving autologous stem cell transplantation and lenalidomide maintenance. Specific aims include characterizing CH prevalence at pre- and post-ASCT timepoints using ultra-deep error-corrected targeted sequencing, testing whether DDR-CH but not age-related CH confers tMN risk, and
- [ConvAD CART: next-generation BCMA CART cells with modular targeting capacities](https://www.myelomasociety.org/award/convad-cart-next-generation-bcma-cart-cells-with-modular-targeting-capacities/) - The curative potential of BCMA CART cells is still suboptimal, with antigen escape and an unfavorable tumor microenvironment contributing to disease relapse. In this project, we aim to overcome these challenges by enhancing established BCMA CART cells with additional multi-antigen specificity by the generation of Conventional and Adapter Dual CART cells (ConvAD CART cells). Our
- [APOBEC3B as a Biomarker and Therapeutic Vulnerability in TP53-aberrant Multiple Myeloma](https://www.myelomasociety.org/award/apobec3b-as-a-biomarker-and-therapeutic-vulnerability-in-tp53-aberrant-multiple-myeloma/) - This project investigates APOBEC3B (A3B) as a biomarker and therapeutic vulnerability in high-risk multiple myeloma with TP53 aberrations. Through the integration of patient-derived datasets, genetically engineered model systems, and primary patient samples, the study aims to define biologically aggressive A3B-high disease states and uncover targetable stress-response dependencies that may inform more precise treatment strategies for
- [Correlation between Unfolded Protein Response (UPR) markers and Thrombosis in Multiple Myeloma](https://www.myelomasociety.org/award/correlation-between-unfolded-protein-response-upr-markers-and-thrombosis-in-multiple-myeloma/) - Over the past two decades, therapeutic advances have continuously improved the management of multiple myeloma, opening up a genuine prospect of cure. However, certain treatment-related side effects remain frequent and may compromise therapeutic efficacy. This is particularly the case for venous thromboembolism, whose risk persists despite the use of pharmacological prophylaxis and validated risk-assessment scores.
- [Uncovering Ferroptosis-Mediated Immune Escape in del(17p) Multiple Myeloma](https://www.myelomasociety.org/award/uncovering-ferroptosis-mediated-immune-escape-in-del17p-multiple-myeloma/) - Deletion of the short arm of chromosome 17 (del(17p)) defines a high-risk multiple myeloma (MM) subtype with poor prognosis and therapy resistance, yet its impact on tumor–immune interactions and specific vulnerabilities remain understood. Using a novel isogenic del(17p) MM model generated by Dr Fulciniti´s laboratory at Dana-Farber Cancer Institute, we identified broad transcriptomic reprogramming including
- [Multimodal investigation of myeloma-recognizing T cells, their transcriptional features and clinical relevance](https://www.myelomasociety.org/award/multimodal-investigation-of-myeloma-recognizing-t-cells-their-transcriptional-features-and-clinical-relevance/) - T cells play a critical role in immune surveillance against multiple myeloma (MM), yet their spontaneous reactivity to MM remains poorly understood. This project aims to systematically investigate MM-recognizing T cells, their transcriptional profiles, and their clinical relevance, with the goal of advancing immunotherapeutic strategies for MM and providing a computational tool to the community
- [Identify high-risk disease in multiple myeloma through single cell detection of highly proliferative (PR) cells](https://www.myelomasociety.org/award/identify-high-risk-disease-in-multiple-myeloma-through-single-cell-detection-of-highly-proliferative-pr-cells/) - This project investigates the biological and microenvironmental mechanisms that drive the development of highly proliferative (PR) subclones in patients with newly diagnosed multiple myeloma. Preliminary data from a single-cell analysis indicate that PR subclones are prevalent at relapse, predict shorter progression-free survival, and proliferate under treatment pressure. The first aim is to define the transcriptomic
- [Development of novel extracellular vesicle (EV)/exosome-based treatment for multiple myeloma: therapeutic potential of miR125b-containing osteoblast-derived EVs](https://www.myelomasociety.org/award/development-of-novel-extracellular-vesicle-ev-exosome-based-treatment-for-multiple-myeloma-therapeutic-potential-of-mir125b-containing-osteoblast-derived-evs/) - EVs are of interest as cell-to-cell communicators that transport microRNAs (miRs) to target cells. Mature osteoblasts (OBs) have been reported to produce anti-myeloma (MM) activity in contrast to their precursors, bone marrow stromal cells/mesenchymal stem cells. We found the critical role of OB-derived EVs (OB-EVs) in induction of MM cell death without impairing normal hematopoietic
- [Transforming Multiple Myeloma Care in Sub-Saharan Africa: Developing a Population-Specific Next Generation Sequencing Panel Based on Long-Read Whole Genome Sequencing to Enhance Treatment Outcomes in Multiple Myeloma Patients](https://www.myelomasociety.org/award/transforming-multiple-myeloma-care-in-sub-saharan-africa-developing-a-population-specific-next-generation-sequencing-panel-based-on-long-read-whole-genome-sequencing-to-enhance-treatment-outcomes-in/) - With support from the International Myeloma Society, this project aims to revolutionize the diagnosis and treatment of Multiple Myeloma (MM) in Sub-Saharan Africa. MM patients in the region often face late diagnoses and limited access to genomic tools that guide personalized care. Current treatment strategies are based on data from non-African populations, overlooking the unique
- [Spatial and Deep Learning Approaches to Predict Early Progression in Smoldering Multiple Myeloma](https://www.myelomasociety.org/award/spatial-and-deep-learning-approaches-to-predict-early-progression-in-smoldering-multiple-myeloma/) - Smoldering multiple myeloma (SMM) represents a common precursor stage to active multiple myeloma (MM), yet accurately predicting early progression in SMM remains a challenge. Traditional risk models, such as the Mayo 20-2-20 system rely on disease burden parameters and have been validated to predict the risk of progression to active myeloma but fail to capture
- [Unlocking Precision Medicine in Refractory Multiple Myeloma](https://www.myelomasociety.org/award/unlocking-precision-medicine-in-refractory-multiple-myeloma/) - Resistance to therapy remains a significant challenge in multiple myeloma, often driven by the substantial genetic heterogeneity inherent to this disease. This now includes resistance to state-of-the-art immunotherapies targeting BCMA. To address this critical challenge, we propose to develop a novel, multi-agent therapeutic strategy designed to overcome resistance and improve outcomes for patients with relapsed
- [Evaluating NKp30-Directed Bispecific NK Cell Engagers for Multiple Myeloma Therapy](https://www.myelomasociety.org/award/evaluating-nkp30-directed-bispecific-nk-cell-engagers-for-multiple-myeloma-therapy/) - Immunotherapy with monoclonal antibodies and their use in combination with proteasome inhibitors and immunomodulatory agents have revolutionized treatment of multiple myeloma (MM). Chimeric antigen receptor (CAR) T cells and bispecific T cell engagers (TCE) further improved the outcome of a substantial number of patients. Nevertheless, for relapsed/refractory myeloma (RRMM) patients there is still a high
- [The development of amyloid subtype-specific CAR-phagocytes for AL Amyloidosis therapy](https://www.myelomasociety.org/award/the-development-of-amyloid-subtype-specific-car-phagocytes-for-al-amyloidosis-therapy/) - Light chain (AL) amyloidosis is a fatal plasma cell disorder related to multiple myeloma, characterized by clonal plasma cells that produce excess misfolded immunoglobulin light chains—either the κ or λ subtype—which aggregate into amyloid fibrils, causing organ damage and ultimately leading to death. Current therapies targeting plasma cells can suppress further fibril production but do
- [Armored CARs to overcome sialylation mediated resistance in Multiple Myeloma](https://www.myelomasociety.org/award/armored-cars-to-overcome-sialylation-mediated-resistance-in-multiple-myeloma/) - Chimeric Antigen Receptor T (CAR-T) cell therapy has revolutionized the treatment of refractory B-cell malignancies. Nevertheless, in multiple myeloma (MM), despite a high rate of initial response, these responses tend not to be durable, important contributory factors including intrinsic cancer cell resistance and immune suppression within the tumor microenvironment (TME). Emerging evidence highlights the role
- [Development of an optimized dual-targeted tandem VH-only fully-human CAR to generate long-term durable remission with adoptive cellular therapy for multiple myeloma](https://www.myelomasociety.org/award/development-of-an-optimized-dual-targeted-tandem-vh-only-fully-human-car-to-generate-long-term-durable-remission-with-adoptive-cellular-therapy-for-multiple-myeloma/) - This project aims to develop an optimized dual-targeted tandem VH-only fully-human CAR for the treatment of multiple myeloma, aiming to achieve durable remissions. Specific aims include analyzing factors associated with CAR T cell manufacturing success, predicting CAR T cell expansion post-infusion, correlating T cell composition with side effects, identifying markers for treatment response and resistance,
- [Application of mass spectrometry for the diagnosis and monitoring of real life patients with monoclonal gammopathies](https://www.myelomasociety.org/award/application-of-mass-spectrometry-for-the-diagnosis-and-monitoring-of-real-life-patients-with-monoclonal-gammopathies/) - The research plan aims to assess the utility of mass spectrometry (MS) for diagnosing and monitoring patients with multiple myeloma (MM), amyloidosis (AL), and Waldenström's macroglobulinemia (WM). Specific aims include comparing MS with standard methods like serum protein electrophoresis (SPEP) and immunofixation (IFE) for identifying and quantifying monoclonal proteins, evaluating MS's ability to detect minimal
- [Investigation of the molecular mechanism of GCK-inhibition as therapeutic approach in multiple myeloma](https://www.myelomasociety.org/award/investigation-of-the-molecular-mechanism-of-gck-inhibition-as-therapeutic-approach-in-multiple-myeloma/) - In over half of multiple myeloma patients, RAS mutation is prevalent, presenting a currently undruggable target. Previous research conducted by the Lentzsch Lab revealed an upregulation of germinal center kinase (GCK) associated with RAS mutations, offering a new therapeutic approach (Li et al., Blood, 2021). Inhibition of GCK, achieved through either knockout or drug intervention,
- [Modeling, unraveling, and beating acquired resistance to BCMA and GPRC5D targeted agents in multiple myeloma](https://www.myelomasociety.org/award/modeling-unraveling-and-beating-acquired-resistance-to-bcma-and-gprc5d-targeted-agents-in-multiple-myeloma-2/) - In the current proposal we will use our recently developed mouse models of MM (Larrayoz et al, Nature Medicine 2023) carrying a new set of humanized therapeutic targets (BCMA and GPRC5D in MM cells and CD3 in T cells), with the aim of testing bi-specific antibodies in clinical use that otherwise cannot be tested against
- [Molecular characterization and therapeutic targeting of Protein Kinase D2 in t(4;14) multiple myeloma](https://www.myelomasociety.org/award/molecular-characterization-and-therapeutic-targeting-of-protein-kinase-d2-in-t414-multiple-myeloma/) - This project aims to molecularly characterize and target Protein Kinase D2 (PRKD2) in t(4;14) multiple myeloma (MM), a high-risk subgroup of MM with poor outcomes. Specific aims include validating the functional role of PRKD2 in MM cells through transcriptomic and epigenomic studies, and evaluating the therapeutic potential of targeting PRKD2 and its downstream pathways using
- [Single cell dissection of autologous apheresis products to predict successful manufacturing, safe application and response to chimeric antigen receptor T-cells in newly diagnosed and relapsed myeloma](https://www.myelomasociety.org/award/single-cell-dissection-of-autologous-apheresis-products-to-predict-successful-manufacturing-safe-application-and-response-to-chimeric-antigen-receptor-t-cells-in-newly-diagnosed-and-relapsed-myeloma/) - This project aims to dissect chimeric antigen receptor (CAR) T cell therapy in myeloma patients at a single-cell resolution to understand the factors influencing treatment success. Specific aims include analyzing factors associated with CAR T cell manufacturing success and failures, predicting CAR T cell expansion post-infusion, correlating T cell composition with side effects, identifying markers
- [USB|CAR-T: Using CRISPR 2.0 to Generate Universal SLAMF7/BCMA CAR-T Cells for Treating Multiple Myeloma](https://www.myelomasociety.org/award/usbcar-t-using-crispr-2-0-to-generate-universal-slamf7-bcma-car-t-cells-for-treating-multiple-myeloma/) - The project focuses on developing a novel CAR-T cell therapy aimed at treating multiple myeloma by utilizing advanced gene editing technologies to engineer a universal CAR-T cell product targeting SLAMF7 and BCMA. The approach involves strategic gene modifications to enhance the therapy's compatibility and effectiveness while minimizing immune rejection and reducing the risk of adverse
- [BCL2L1 armored CAR T cells overcome exhaustion and enhance persistence in multiple myeloma](https://www.myelomasociety.org/award/bcl2l1-armored-car-t-cells-overcome-exhaustion-and-enhance-persistence-in-multiple-myeloma/) - The specific aims of this proposed study aim to enhance CAR T cell therapy for multiple myeloma by addressing the mechanisms of resistance and improving persistence of CAR T cells armored with BCL-xL. Aim 1 seeks to determine the role of MM cell death ligands in the resistance of BCL-xL armored CARs to activation-induced cell
- [DESTINY - Detecting Spatial Heterogeneity in Multiple Myeloma patients through a Liquid Biopsy approach](https://www.myelomasociety.org/award/destiny-detecting-spatial-heterogeneity-in-multiple-myeloma-patients-through-a-liquid-biopsy-approach/) - Multiple Myeloma (MM) is a clonal plasma cell (PC) proliferative disorder characterized by the proliferation in the bone marrow of a plasma cell clone, which synthesizes monoclonal immuno-globulins; in the most aggressive cases, or in the advanced stages of the disease, the plasma cell clone tends to infiltrate other parts of the body. Genomic studies
- [GCK inhibition as a new therapeutical approach in RASMut myeloma and possible strategy to overcome therapy resistance](https://www.myelomasociety.org/award/gck-inhibition-as-a-new-therapeutical-approach-in-rasmut-myeloma-and-possible-strategy-to-overcome-therapy-resistance/) - RAS mutations in multiple myeloma lead to increased germinal center kinase (GCK) expression, presenting a potential new therapeutic target. Inhibiting GCK (GCKi) has shown to reduce myeloma cell proliferation in both in vitro and in vivo models (Li et al., Blood, 2021). Additionally, unlike IMiDs, GCKi promotes the proteasomal degradation of IKZF1/3 through a pathway
- [Evaluation of single nucleotide variants in DNA repair and cell cycle control genes in multiple myeloma patients undergoing hematopoietic stem cell transplant and their association with clinical outcomes](https://www.myelomasociety.org/award/evaluation-of-single-nucleotide-variants-in-dna-repair-and-cell-cycle-control-genes-in-multiple-myeloma-patients-undergoing-hematopoietic-stem-cell-transplant-and-their-association-with-clinical-outco/) - Autologous Stem Cell Transplantation represents a widely accessible therapy in Latin America, particularly crucial given the limited availability of new medications in the region, including monoclonal antibodies, next-generation proteasome inhibitors, immunomodulators, and advanced cellular therapies. This study aims to assess the impact of the genetic profile, particularly single nucleotide variants (SNVs), on the clinical outcomes
- [A scalable manufacturing platform for externally controllable universal CAR T-cell products](https://www.myelomasociety.org/award/a-scalable-manufacturing-platform-for-externally-controllable-universal-car-t-cell-products/) - Chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough in cancer treatment and has achieved unprecedented success in hematologic malignancies. Recent advances in autologous CAR T-cell therapies utilize a patient's own immune T cells, but ""off-the-shelf"" allogeneic CAR T cells have many potential advantages over autologous approaches, including immediate availability of cryopreserved batches, potential standardization
- [Identifying Mechanisms of Response and Resistance to BCMA CAR-T Therapy in Multiple Myeloma and Extramedullary Disease](https://www.myelomasociety.org/award/identifying-mechanisms-of-response-and-resistance-to-bcma-car-t-therapy-in-multiple-myeloma-and-extramedullary-disease/) - Chimeric antigen receptor (CAR)-T cell therapy has emerged as an effective therapeutic approach in multiple myeloma (MM), where two B cell maturation antigen (BCMA)-targeting CAR-T products, ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), are currently approved in the relapsed/refractory MM (RRMM) setting. The outstanding outcomes manifested in overall response rates (ORR) above 70% in heavily
- [BAtMMaN: Bone marrow AdipocyTes in the Multiple MyelomA Niche](https://www.myelomasociety.org/award/batmman-bone-marrow-adipocytes-in-the-multiple-myeloma-niche/) - Aging and obesity are the two main risk risk factors for multiple myeloma tumorigenesis, and both are characterized by an increase in bone adiposity, suggesting a crucial role for bone marrow adipocytes in cancer development. Previous research suggests that bone marrow adiposity influences plasma cell transformation, proliferation and resistance to therapy, and reciprocal interactions can
- [Investigating the Impact of Vaccinations on the Development and Course of Monoclonal Gammopathies: A Comprehensive Analysis](https://www.myelomasociety.org/award/investigating-the-impact-of-vaccinations-on-the-development-and-course-of-monoclonal-gammopathies-a-comprehensive-analysis/) - This research is a part of my doctoral project, aiming to examine the role of vaccinations against specific pathogens in the development and progression of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma (MM). The study leverages two unique cohorts: the Icelandic iStopMM study, which has screened over 75,000 individuals for MGUS, and the
- [Modeling, unraveling, and beating acquired resistance to BCMA and GPRC5D targeted agents in multiple myeloma](https://www.myelomasociety.org/award/modeling-unraveling-and-beating-acquired-resistance-to-bcma-and-gprc5d-targeted-agents-in-multiple-myeloma/) - Acquired therapeutic resistance constitutes a major limitation to achieve a cure for multiple myeloma (MM). In this context, CAR T-cell and bispecific antibodies against BCMA and GPRC5D antigens have shown promising results, but most patients develop acquired resistance and eventually relapse. While acquired BCMA and GPRC5D inactivation leading to resistant disease has been reported following
- [Bone marrow inflammation as driver of multiple myeloma persistence and relapse](https://www.myelomasociety.org/award/bone-marrow-inflammation-as-driver-of-multiple-myeloma-persistence-and-relapse/) - The specific aims of this research focus on understanding the role of inflammatory mesenchymal stromal cells (iMSC) and bone marrow inflammation in multiple myeloma (MM) development and treatment response. Aim 1 aims to investigate the effect of novel treatments, including bispecific T cell engagers, on normalizing bone marrow inflammation and iMSC presence. Aim 2 seeks
- [TARGETING LOSS OF THE TUMOR SUPPRESSOR TENT5C IN MULTIPLE MYELOMA](https://www.myelomasociety.org/award/targeting-loss-of-the-tumor-suppressor-tent5c-in-multiple-myeloma/) - This project aims to target the loss of the tumor suppressor TENT5C in multiple myeloma (MM). The primary goal is to investigate the effect of pathway-specific inhibitors in MM patients with biallelic TENT5C abnormalities. Additionally, the project seeks to identify novel synthetic lethality pathways associated with the loss of TENT5C in MM. Preliminary data suggest
- [Novel immunotherapy investigation and characterization of immune escape mechanisms to Natural Killer cells in Multiple Myeloma](https://www.myelomasociety.org/award/novel-immunotherapy-investigation-and-characterization-of-immune-escape-mechanisms-to-natural-killer-cells-in-multiple-myeloma/) - Despite the significant improvement in multiple myeloma (MM) survival owing to novel treatments, 15-20% of MM patients experience relapse or a refractory disease, thus novel therapeutic options are needed. Natural killer (NK) cells an emerging promising option, especially in patients resistant to T-cell based immunotherapies. However, our recently published data on cell lines show that
- [DISCOVER NUTRIENTS - Understanding the relationship between nutrition and microbiome in MM](https://www.myelomasociety.org/award/discover-nutrients-understanding-the-relationship-between-nutrition-and-microbiome-in-mm/) - This project aims to investigate the relationship between diet, microbiome composition, and response to standard-of-care treatment in newly diagnosed multiple myeloma (NDMM) patients. Stool samples from 150 NDMM patients will be analyzed alongside dietary data collected through interviews. These findings will be correlated with metabolome biomarkers using serum mass spectrometry. Patient-derived results will be validated
- [Characterizing the emergence of T cell dysfunction as a cause of therapy failure and disease progression in multiple myeloma](https://www.myelomasociety.org/award/characterizing-the-emergence-of-t-cell-dysfunction-as-a-cause-of-therapy-failure-and-disease-progression-in-multiple-myeloma/) - Using comprehensive immune profiling techniques, I will investigate the role that immune dysfunction plays throughout the myeloma disease course. This includes immune profiling in patients with newly diagnosed multiple myeloma on immunomodulatory drugs as well as in relapsed or refractory multiple myeloma patients receiving bispecific antibodies. Through this immune profiling we hope to identify immune
- [Flow cytometry as a tool for the study of the tumor microenvironment in multiple myeloma](https://www.myelomasociety.org/award/flow-cytometry-as-a-tool-for-the-study-of-the-tumor-microenvironment-in-multiple-myeloma/) - The bone marrow (BM) microenvironment in multiple myeloma has been recognized as an important player in the development of the tumor, that allows the homing of clonal plasma cells (PC) to the BM; the spread of tumor by the bloodstream to a second site; the generation of paracrine factors that are involved in the survival,
- [Dissecting the mechanisms of Multiple Myeloma (MM) resistance to Natural Killer (NK) cells and the role of NK cells-macrophage interaction in MM immune-evasion](https://www.myelomasociety.org/award/dissecting-the-mechanisms-of-multiple-myeloma-mm-resistance-to-natural-killer-nk-cells-and-the-role-of-nk-cells-macrophage-interaction-in-mm-immune-evasion/) - The study aims to investigate mechanisms of Multiple Myeloma (MM) resistance to Natural Killer (NK) cells and the role of NK cells' interaction with macrophages in immune evasion. Aim 1 focuses on validating candidate NK cell resistance genes identified from previous functional genomic screens, using CRISPR editing and activation techniques on MM cell lines. This
- [Spatial and temporal tumor genomic heterogeneity in extramedullary multiple myeloma and solitary plasmacytoma with minimal marrow involvement](https://www.myelomasociety.org/award/spatial-and-temporal-tumor-genomic-heterogeneity-in-extramedullary-multiple-myeloma-and-solitary-plasmacytoma-with-minimal-marrow-involvement/) - To test the hypothesis that plasmacytomas can represent spatial and temporal clonal escape events, featuring distinct myeloma-defining genomic events characteristic of active disease, through the following specific aims: Aim 1. Compare genomic driver events in paired samples from patients with newly diagnosed solitary plasmacytoma (SP) with minimal marrow involvement versus newly diagnosed multiple myeloma (NDMM)
- [Discovering and targeting unprecedented mitochondrial vulnerabilities against multiple myeloma](https://www.myelomasociety.org/award/discovering-and-targeting-unprecedented-mitochondrial-vulnerabilities-against-multiple-myeloma/) - This research aims to target mitochondrial vulnerabilities in multiple myeloma (MM) by focusing on ClpP, a mitochondrial protease highly expressed in MM cells. Leveraging ClpP's importance for MM cell survival, the study seeks to understand its function and identify novel mitochondrial vulnerabilities. Using functional geno-proteomics and genetic screening, the research aims to achieve two main
- [Targeting the bone marrow niche in Multiple Myeloma](https://www.myelomasociety.org/award/targeting-the-bone-marrow-niche-in-multiple-myeloma/) - This research identifies MM-specific bone marrow mesenchymal stromal cells (iMSC) as crucial components of the pro-tumor microenvironment in Multiple Myeloma (MM). These iMSCs support MM cell survival and proliferation and are associated with bone marrow inflammation. Despite successful induction treatment, iMSC presence persists, potentially contributing to therapy resistance and relapse. The study aims to determine
- [Glutamine metabolism as new marker and diagnostic tool for bone diseases in mm patients](https://www.myelomasociety.org/award/glutamine-metabolism-as-new-marker-and-diagnostic-tool-for-bone-diseases-in-mm-patients/) - The rationale of this research translational project has been to investigate the role of glutamine (Gln) and glutamate metabolism as possible new diagnostic tools for MM bone disease in MM patients. The aims of the project were: -Firstly, to check how the alteration of Gln metabolisms induced by MM cells and consequently the Gln addicted
- [Chimeric antigen receptor T cells secreting IL-12 and anti-IL-6 to enhance responses in multiple myeloma](https://www.myelomasociety.org/award/chimeric-antigen-receptor-t-cells-secreting-il-12-and-anti-il-6-to-enhance-responses-in-multiple-myeloma/) - The study aims to enhance the efficacy of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) by engineering CAR-T cells to secrete interleukin-12 (IL-12) and an anti-IL-6 single domain antibody (sdAb). While current CAR-T therapies targeting BCMA show promising response rates, median progression-free survival remains short, indicating the need for improved strategies. The
- [Targeting TF (CD142) as a new target for CAR-NK cell immunotherapy in multiple myeloma](https://www.myelomasociety.org/award/targeting-tf-cd142-as-a-new-target-for-car-nk-cell-immunotherapy-in-multiple-myeloma/) - Multiple myeloma (MM) is a bone marrow-resident hematologic malignancy of plasma cells and the second most diagnosed blood cancer, after non-Hodgkin lymphoma. Despite the development of myeloma-targeted immunotherapies, MM remains largely incurable. The objective of this research is to evaluate tissue factor (TF, also known as coagulation factor III and CD142) as a new target
- [Exploring APOBECs as therapeutic vulnerabilities in Multiple Myeloma](https://www.myelomasociety.org/award/exploring-apobecs-as-therapeutic-vulnerabilities-in-multiple-myeloma/) - The project aims to explore APOBECs as potential therapeutic targets in multiple myeloma (MM). Aim 1 focuses on identifying druggable APOBEC targets by modulating their expression in MM cells and assessing their impact on cellular characteristics. This involves genetic manipulations and functional assays to determine downstream pathways affected by APOBEC activation. Aim 2 investigates the
- [GCK, a new therapeutic target for undruggable RAS in myeloma treatment](https://www.myelomasociety.org/award/gck-a-new-therapeutic-target-for-undruggable-ras-in-myeloma-treatment/) - The project aims to investigate GCK as a therapeutic target for RAS-mutated multiple myeloma (MM), where current treatments are lacking. RAS pathway mutations are common in MM, driving disease progression, yet no RAS inhibitors are clinically available. GCK, a key player in B cell differentiation, has been found critical for MM cell survival and growth,
- [PNC-27: A Novel Effective Strategy for Targeting the Achilles' Heel of Multiple Myeloma](https://www.myelomasociety.org/award/pnc-27-a-novel-effective-strategy-for-targeting-the-achilles-heel-of-multiple-myeloma/) - The project focuses on using the anticancer peptide PNC-27, which targets the p53 pathway, as a potential therapeutic approach for multiple myeloma (MM). While MM with high-risk features like TP53 deletion has poorer outcomes, PNC-27 has shown promising results in cancer cells, including MM, by inducing cell death. Despite the absence of MDM2 on MM
- [Immunogenomics-guided adaptive cellular therapies in Multiple Myeloma](https://www.myelomasociety.org/award/immunogenomics-guided-adaptive-cellular-therapies-in-multiple-myeloma/) - This proposal aimed to interrogate at single cell level the tumor microenvironment of CAR-T and TCE treated MM patients to elucidate the immune-mediated causes of resistance, identify potential means to reverse tolerance, and study how genomics might predict which patients should benefit the most from T-cell based therapies.
- [Development of novel targeted therapies for multiple myeloma](https://www.myelomasociety.org/award/development-of-novel-targeted-therapies-for-multiple-myeloma/) - The overarching goal of this study was to characterize and develop strategies to harness the immunomodulatory properties of the NF-kB inhibitor IT848 for multiple myeloma (MM) therapy. IT848 is a novel small molecule NF-κB inhibitor that we recently developed as a joint effort with our biotech partner ImmuneTarget Inc. IT848 is a direct inhibitor of
- [Dissecting and appraising novel mitochondrial vulnerabilities against multiple myeloma](https://www.myelomasociety.org/award/dissecting-and-appraising-novel-mitochondrial-vulnerabilities-against-multiple-myeloma/) - The study investigates mitochondria as crucial signaling hubs in cancer cells, particularly in multiple myeloma (MM), which may rely heavily on mitochondrial functions due to heightened stress experiences. The research focuses on the mitochondrial matrix protease ClpP, found to be essential for myeloma cell survival. Initial findings revealed ClpP's role in regulating housekeeping autophagy and
- [Improving immune surveillance in high-risk Multiple Myeloma patients](https://www.myelomasociety.org/award/improving-immune-surveillance-in-high-risk-multiple-myeloma-patients/) - Dr. Francesca Cottini is an Assistant Professor in the Division of Hematology at the Ohio State University and IMS member since 2020. She is a physician scientist with clinical and research expertise in Multiple Myeloma (MM). She mastered translational and basic research as a post-doctoral fellow at Harvard Medical School in the laboratory of Dr.
- [Immunotherapy for Multiple Myeloma: A New Generation of Chimeric Antigen Receptors and Immune Checkpoint Blockade](https://www.myelomasociety.org/award/immunotherapy-for-multiple-myeloma-a-new-generation-of-chimeric-antigen-receptors-and-immune-checkpoint-blockade/) - Chimeric Antigen Receptor (CAR) T-cells targeting B-cell maturation antigen (BCMA) have proven outstanding efficacy and are a promising option for patients with relapsed/refractory multiple myeloma (MM), but no plateau is observed in progression-free survival (PFS) curves and relapses happen. One of the mechanisms of relapse is impaired T-cell persistence/potency due to T-cell exhaustion. Checkpoint inhibitory
- [Amyloid Targeting CAR Macrophage Therapy Against AL Amyloidosis](https://www.myelomasociety.org/award/amyloid-targeting-car-macrophage-therapy-against-al-amyloidosis/) - Amyloid light chain (AL) amyloidosis is an incurable rare monoclonal plasma cell dyscrasia closely related to multiple myeloma. The clonal plasma cells produce excessive misfolded monoclonal immunoglobulin light chains, forming extracellular insoluble fibrils, destroying tissue architecture, causing functional organ damage, and eventually leading to death. Current chemotherapies only target clonal plasma cells to suppress the
- [Dissecting the functional role of APOBEC3B in multiple myeloma](https://www.myelomasociety.org/award/dissecting-the-functional-role-of-apobec3b-in-multiple-myeloma/) - AIM 1 aims to identify APOBEC3B (A3B) targets and pathways affected in multiple myeloma (MM) cells. Using knockdown and overexpression techniques, researchers will assess the functional impact of A3B on MM cell viability, proliferation, apoptosis, and DNA damage. RNA-Seq and proteomics will provide mechanistic insights into A3B's role in MM, potentially identifying affected pathways. AIM
- [Democratizing multiple myeloma CAR T cell therapy by in situ programming of virus-specific T cells”](https://www.myelomasociety.org/award/democratizing-multiple-myeloma-car-t-cell-therapy-by-in-situ-programming-of-virus-specific-t-cells/) - The objective of this proposal is to develop antigen-presenting nanoparticles (APNs) to program virus-specific T cells with chimeric antigen receptors (CARs) targeting B-cell maturation antigen (BCMA) for the treatment of multiple myeloma (MM). Currently, CAR T cell therapy for MM is hindered by complex and costly manufacturing processes. By leveraging APNs to program circulating T
- [How to Engage T Cell in Myeloma](https://www.myelomasociety.org/award/how-to-engage-t-cell-in-myeloma/) - The project aims to analyze tumor-infiltrating lymphocytes (TILs) in multiple myeloma patients treated with bispecific T-cell engager (bsAb) therapy, utilizing single-cell analyses to understand T-cell diversity, phenotype dynamics, and specificity. By correlating sequencing data with functional validation of anti-tumor reactivity, the study seeks to predict response to bsAb therapy. This integrated approach, combining clinical expertise
- [TARGETING METABOLIC SWITCH OF HIGH-RISK MULTIPLE MYELOMA CELLS: TOWARDS THE DESIGN OF AN EXPLORATORY APPROACH FOR AN UNMET CLINICAL NEED](https://www.myelomasociety.org/award/targeting-metabolic-switch-of-high-risk-multiple-myeloma-cells-towards-the-design-of-an-exploratory-approach-for-an-unmet-clinical-need/) - Preliminary data suggest that HR landscape promotes metabolic reprogramming to sustain high-proliferation rates accompanied by a higher oxidative state compared with standard risk disease. Given these premises, this project aims to explore the potential benefit of metabolism-targeted therapy in HR-MM patients. For this purpose, we plan: 1) to evaluate multiomics (including genomics, transcriptomics, proteomics) and
- [Systematic functional genomics characterization of 17p13(del) multiple myeloma](https://www.myelomasociety.org/award/systematic-functional-genomics-characterization-of-17p13del-multiple-myeloma/) - This project aims to systematically characterize the functional genomics of 17p13 deletion in multiple myeloma (MM). Aim 1 seeks to identify potential tumor suppressor genes (TSGs) within 17p13 that cooperate with TP53 loss, investigating if haploinsufficiency of these genes contributes to MM pathogenesis. Aim 2 aims to define therapeutic vulnerabilities in MM cells with 17p
- [Deciphering the human plasma cell niche and its transformation in multiple myeloma by highly multiplexed tissue imaging](https://www.myelomasociety.org/award/deciphering-the-human-plasma-cell-niche-and-its-transformation-in-multiple-myeloma-by-highly-multiplexed-tissue-imaging/) - This project aims to comprehensively analyze the spatial organization of the plasma cell niche and its alterations in monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) using CO-Detection by IndEXing (CODEX) multiplex tissue imaging. The study anticipates that cellular interactions within the bone marrow microenvironment generate specific tissue features, which can be identified
- [Patterns of relapse from complete response during different maintenance strategies](https://www.myelomasociety.org/award/patterns-of-relapse-from-complete-response-during-different-maintenance-strategies/) - The aim of the IMS funded project was to investigate whether different subgroups of patients (i.e. defined by baseline clinical and biological characteristics) with newly-diagnosed multiple myeloma who have achieved a complete response (CR) after autologous stem cell transplantation (ASCT) benefit from different maintenance treatments or if some of them even require observation only. Due
- [The permissive immune microenvironment is a critical regulator of disease progression from SMM to overt MM, and defining these alterations is critical for the development of translational prognostic and mechanistic models of disease progression](https://www.myelomasociety.org/award/the-permissive-immune-microenvironment-is-a-critical-regulator-of-disease-progression-from-smm-to-overt-mm-and-defining-these-alterations-is-critical-for-the-development-of-translational-prognostic-a/) - Novel genomic approaches may enable better prediction of progression risk to multiple myeloma (MM) from the more indolent precursor stages of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). In support of this, the Ghobrial and Getz laboratories have previously collected, analyzed, and published biomarkers from the tumor cell fraction of SMM
- [BCMA-iNKT-CAR for the Treatment of Multiple Myeloma](https://www.myelomasociety.org/award/bcma-inkt-car-for-the-treatment-of-multiple-myeloma/) - The goal of this project was to test and characterize a BCMA targeted chimeric antigen receptor (CAR) that we expressed on invariant natural killer T cells (iNKT) for the treatment of multiple myeloma. The advantage of iNKT cells is that they do not cause GvDH, so are a potential "off the shelf" product which means
- [Early Detection and Intervention in Smoldering Multiple Myeloma: Population-Based Screening and Treatment (Edit-SMM)](https://www.myelomasociety.org/award/early-detection-and-intervention-in-smoldering-multiple-myeloma-population-based-screening-and-treatment-edit-smm/) - The Edit-SMM project aims to revolutionize the management of smoldering multiple myeloma (SMM). Building on the iStopMM study, it seeks to improve early detection and treatment to potentially prevent the progression to full-blown multiple myeloma (MM), enhancing patient outcomes. The Edit-SMM analyzes epidemiological data, assesses the efficacy and safety of early treatments, and employs novel
- [LIQUID BIOPSY IN MYELOMA TO INFORM OUTCOME AND TREATMENT DECISIONS](https://www.myelomasociety.org/award/liquid-biopsy-in-myeloma-to-inform-outcome-and-treatment-decisions/) - The proposal aims to revolutionize the assessment and treatment of multiple myeloma (MM) by introducing liquid biopsy techniques as alternatives to invasive bone marrow biopsies. Despite recent therapeutic advances, MM remains incurable, necessitating frequent biopsies for optimal treatment. However, standard bone marrow biopsies have limitations, such as representing only a single site and missing dynamic
- [Optimizing Melphalan dose among older adults with Multiple Myeloma receiving Autologous Stem Cell Transplantation](https://www.myelomasociety.org/award/optimizing-melphalan-dose-among-older-adults-with-multiple-myeloma-receiving-autologous-stem-cell-transplantation/) - This research project focuses on optimizing melphalan dosing for older adults undergoing autologous stem cell transplantation (ASCT) for multiple myeloma (MM). While ASCT with high-dose melphalan is effective, older adults are at increased risk of severe toxicities, impacting their quality of life. Currently, there's uncertainty about the appropriate melphalan dose for older adults, with many
- [Investigating the molecular mechanisms of microenvironment-dependent immune escape to natural killer cells in myeloma to uncover biomarkers for rational combination treatment strategie](https://www.myelomasociety.org/award/investigating-the-molecular-mechanisms-of-microenvironment-dependent-immune-escape-to-natural-killer-cells-in-myeloma-to-uncover-biomarkers-for-rational-combination-treatment-strategie/) - The research project aims to understand the molecular mechanisms behind microenvironment-dependent immune escape to natural killer (NK) cells in myeloma, with the goal of identifying biomarkers for rational combination treatment strategies. Aim 1 involves validating candidate markers of NK cell resistance and investigating NK cell adaptive changes in primary myeloma samples at different disease stages
- [Role of flow cytometry and especially its use in the definition of the measurable residual disease (MRD) in multiple myeloma](https://www.myelomasociety.org/award/role-of-flow-cytometry-and-especially-its-use-in-the-definition-of-the-measurable-residual-disease-mrd-in-multiple-myeloma/) - This project aims to develop a clinically useful method for monitoring treatment response in multiple myeloma (MM) by detecting circulating tumor cells in peripheral blood (PB) using next-generation flow cytometry. The proposed approach, called BLOOD-FLOW, involves optimizing immunomagnetic enrichment of circulating plasma cells from large PB volumes, achieving a limit of detection two logs more
- [Immune cell contribution to drug-resistance in Multiple Myeloma](https://www.myelomasociety.org/award/immune-cell-contribution-to-drug-resistance-in-multiple-myeloma/) - Utilizing longitudinal bone marrow samples from relapsed-refractory MM patients treated with Elotuzumab-Iberdomide-Dexamethasone (EId), the study aims to evaluate immunologic profiles and specific biomarkers such as IKZF1 in immune cells. The project has three specific aims: 1) to profile the immune system of MM patients before EId treatment to identify correlations with high-risk MM phenotypes, 2)
- [Ancestrality of genomic alterations in Multiple Myeloma: impact on the clonal evolution and on the Minimal Residual Disease dynamics](https://www.myelomasociety.org/award/ancestrality-of-genomic-alterations-in-multiple-myeloma-impact-on-the-clonal-evolution-and-on-the-minimal-residual-disease-dynamics/) - Copy Number Alterations (CNAs) play a key role in the Multiple Myeloma (MM) pathogenesis and prognostic stratification of the disease. For this reason, it is of particular biological and clinical interest to study the temporal occurrence of early alterations over the developmental history of MM. This, in order to identify specific altered chromosomal regions or
- [Investigating CREB1 signaling as a novel therapeutic target in multiple myeloma](https://www.myelomasociety.org/award/investigating-creb1-signaling-as-a-novel-therapeutic-target-in-multiple-myeloma/) - Multiple myeloma (MM) is a rare neoplastic disorder characterized by uncontrolled clonal proliferation of malignant plasma cells in the bone marrow (BM). In the last decade, the therapeutic approaches to treat MM patients have been improved. Nevertheless, the urgent need to identify new therapeutic targets remains to develop more effective strategies against this uncurable disease.
- [Biomarkers for monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma](https://www.myelomasociety.org/award/biomarkers-for-monoclonal-gammopathy-of-undetermined-significance-mgus-and-multiple-myeloma/) - In this collaborative research project, we aim to identify and develop blood biomarkers improving MGUS follow-up. To achieve this, blood-based proteomic analysis using untargeted i3-D/LC mass spectrometry in unique prospective longitudinal blood samples (n=880) collected in participants of the Northern Sweden Health and Disease Study (Umeå University, Sweden) is performed. Routine and novel biomarkers will
- [Evaluation of single nucleotide polymorphisms of BRCA1, CDKN1A, TP53BP, and XRCC1 in multiple myeloma patients undergoing hematopoietic stem cells transplant and their association with clinical outcomes](https://www.myelomasociety.org/award/evaluation-of-single-nucleotide-polymorphisms-of-brca1-cdkn1a-tp53bp-and-xrcc1-in-multiple-myeloma-patients-undergoing-hematopoietic-stem-cells-transplant-and-their-association-with-clinical-outcom/) - Autologous Stem Cell Transplantation represents a widely accessible therapy in Latin America, particularly crucial given the limited availability of new medications in the region, including monoclonal antibodies, next-generation proteasome inhibitors, immunomodulators, and advanced cellular therapies. This study aims to assess the impact of the genetic profile, particularly single nucleotide variants (SNVs), on the clinical outcomes

## Episodes

- [Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial](https://www.myelomasociety.org/belantamab-mafodotin-bortezomib-and-dexamethasone-vs-daratumumab-bortezomib-and-dexamethasone-in-relapsed-refractory-multiple-myeloma-overall-survival-analysis-and-updated-efficacy-outcomes-of-th/)
- [Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial](https://www.myelomasociety.org/phase-3-study-of-teclistamab-tec-in-combination-with-lenalidomide-len-and-tec-alone-versus-len-alone-in-newly-diagnosed-multiple-myeloma-ndmm-as-maintenance-therapy-following-autologous-stem-cel/)
- [Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)](https://www.myelomasociety.org/isatuximab-lenalidomide-bortezomib-and-dexamethasone-induction-therapy-for-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma-final-progression-free-survival-analysis-of-part-1-of-a/)
- [Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial](https://www.myelomasociety.org/phase-2-registrational-study-of-anitocabtagene-autoleucel-for-the-treatment-of-patients-with-relapsed-and-or-refractory-multiple-myeloma-preliminary-results-from-the-immagine-1-trial/)
- [ The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma](https://www.myelomasociety.org/the-ifm2017-03-phase-3-trial-a-dexamethasone-sparing-regimen-with-daratumumab-and-lenalidomide-for-frail-patients-with-newly-diagnosed-multiple-myeloma/)
- [Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial](https://www.myelomasociety.org/phase-2-study-of-teclistamab-based-induction-regimens-in-patients-with-transplant-eligible-te-newly-diagnosed-multiple-myeloma-ndmm-results-from-the-gmmg-hd10-dsmm-xx-majestec-5-trial/)
- [First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)](https://www.myelomasociety.org/first-results-of-a-phase-1-first-in-human-dose-escalation-study-of-isb-2001-a-bcmaxcd38xcd3-targeting-trispecific-antibody-in-patients-with-relapsed-refractory-multiple-myeloma-rrmm/)
- [Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience With Updated Follow-up](https://www.myelomasociety.org/safety-and-efficacy-of-standard-of-care-ciltacabtagene-autoleucel-cilta-cel-for-relapsed-refractory-multiple-myeloma-rrmm-real-world-experience-with-updated-follow-up/)
- [Efficacy and safety of Isa-KRd induction before  response-adapted consolidation in transplant eligible newly diagnosed multiple myeloma: an interim analysis of the  IFM2020-02 MIDAS study.](https://www.myelomasociety.org/efficacy-and-safety-of-isa-krd-induction-before-response-adapted-consolidation-in-transplant-eligible-newly-diagnosed-multiple-myeloma-an-interim-analysis-of-the-ifm2020-02-midas-study/)
- [Single-cell RNA-sequencing of 6 million tumor and immune cells in patients with plasma cell premalignancy unveils  co-regulation of disease progression by tumor biology and  immune dysregulation](https://www.myelomasociety.org/single-cell-rna-sequencing-of-6-million-tumor-and-immune-cells-in-patients-with-plasma-cell-premalignancy-unveils-co-regulation-of-disease-progression-by-tumor-biology-and-immune-dysregulation/)
- [Single cell analyses of bone marrow immune microenvironment in RRMM subjects treated with MEK1/2 inhibitors reveal IRF1-mediated IFN/PDL1 signaling axes](https://www.myelomasociety.org/single-cell-analyses-of-bone-marrow-immune-microenvironment-in-rrmm-subjects-treated-with-mek1-2-inhibitors-reveal-irf1-mediated-ifn-pdl1-signaling-axes/)
- [Prevention of infections during treatment with bispecific antibodies and CAR T cells in multiple myeloma​](https://www.myelomasociety.org/prevention-of-infections-during-treatment-with-bispecific-antibodies-and-car-t-cells-in-multiple-myeloma/)
- [Importance of Patient-Reported Symptoms and Health-Related Quality of Life for drug approval in MM](https://www.myelomasociety.org/importance-of-patient-reported-symptoms-and-health-related-quality-of-life-for-drug-approval-in-mm/)
- [Development of an academic CAR-T in MM : the Spanish experience](https://www.myelomasociety.org/development-of-an-academic-car-t-in-mm-the-spanish-experience/)
- [Frontline Therapy for transplant ineligible patients: the European perspective](https://www.myelomasociety.org/frontline-therapy-for-transplant-ineligible-patients-the-european-perspective/)
- [Ongoing clinical trials from the Nordic Group](https://www.myelomasociety.org/ongoing-clinical-trials-from-the-nordic-group/)
- [Role of tandem autologous stem cell transplantation for the treatment of multiple myeloma](https://www.myelomasociety.org/role-of-tandem-autologous-stem-cell-transplantation-for-the-treatment-of-multiple-myeloma/)
- [Resistance to bispecific antibodies](https://www.myelomasociety.org/resistance-to-bispecific-antibodies/)
- [Findings from the Australian and New Zealand myeloma and related diseases registry​](https://www.myelomasociety.org/findings-from-the-australian-and-new-zealand-myeloma-and-related-diseases-registry/)
- [Do we need PET-CT to assess response in MM](https://www.myelomasociety.org/do-we-need-pet-ct-to-assess-response-in-mm/)
- [Optimal therapy for young patients with high-risk disease: the European point of view](https://www.myelomasociety.org/optimal-therapy-for-young-patients-with-high-risk-disease-the-european-point-of-view/)
- [Drug access in Brazil; equity actions between Public and Private Health Systems](https://www.myelomasociety.org/drug-access-in-brazil-equity-actions-between-public-and-private-health-systems/)

## Events

- [23rd Annual Meeting & Exposition](https://www.myelomasociety.org/events/23rd-ims-annual-meeting/) - The program is developed solely by the International Myeloma Society. 
- [IMS Community Webinar Series: Optimizing the use of ADCs and TCRTs](https://www.myelomasociety.org/events/ims-community-webinar-series-optimizing-the-use-of-adcs-and-tcrts/) - Format These meetings will be web-based group discussion using case-based approaches. Each session will last 90 minutes with 30 minutes dedicated to didactics. The rest of the time will be dedicated to a panel discussion in an open forum addressing the practical barriers of use of T cell redirected therapies. A curriculum for specific questions
- [8th Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/events/8th-immune-effector-cell-therapies-in-multiple-myeloma-workshop/)
- [4th Annual Workshop on Genomics](https://www.myelomasociety.org/events/4th-annual-workshop-on-genomics/) - Agenda
- [NDMM and RRMM Webinar - West Coast](https://www.myelomasociety.org/events/ndmm-and-rrmm-webinar-west-coast/) - Program
- [NDMM and RRMM Webinar - East Coast](https://www.myelomasociety.org/events/ndmm-and-rrmm-webinar-east-coast/) - Program
- [Educational Workshop in Belgrade, Serbia](https://www.myelomasociety.org/events/educational-workshop-in-belgrade-serbia/) - In Person Registration Admission to scientific sessions. Admission to breakfasts, lunches, and coffee breaks. Certificate of attendance. One-year access to on-demand session recordings. Access instructions will be provided within 3 weeks post-event. On-demand Registration One-year access to on-demand session recordings. Access instructions will be provided within 3 weeks post-event.
- [7th Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/events/7th-immune-effector-cell-therapies-in-multiple-myeloma-workshop/) - Registration Fees In Person Registration Admission to scientific sessions. Admission to breakfasts, lunches, and coffee breaks. Certificate of attendance. One-year access to on-demand session recordings. Access instructions will be provided within 3 weeks post-event. On-demand Registration One-year access to on-demand session recordings. Access instructions will be provided within 3 weeks post-event. Ancillary Meeting Guidelines
- [Myeloma Cure Summit: Definitions, Metrics, and Milestones](https://www.myelomasociety.org/events/myeloma-cure-summit-definitions-metrics-and-milestones/)
- [Relapsed/Refractory Multiple Myeloma Webinar - West Coast](https://www.myelomasociety.org/events/relapsed-refractory-multiple-myeloma-webinar-west-coast/)
- [Relapsed/Refractory Multiple Myeloma Webinar - East Coast](https://www.myelomasociety.org/events/relapsed-refractory-multiple-myeloma-webinar-east-coast/)
- [22nd IMS Annual Meeting](https://www.myelomasociety.org/events/22nd-ims-annual-meeting/) - Land Acknowledgement The International Myeloma Society acknowledges the land this event is held on is the traditional territory of many nations including the Mississaugas of the Credit, the Anishnabeg, the Chippewa, the Haudenosaunee and the Wendat peoples and is now home to many diverse First Nations, Inuit and Métis peoples. We also acknowledge that Toronto
- [Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025](https://www.myelomasociety.org/events/practical-insights-in-and-translational-aspects-of-novel-immune-therapies-in-multiple-myeloma-2/) - The treatment of multiple myeloma has dramatically evolved in recent years with immune-based strategies resulting in a very high impact in the relapsed refractory setting. Several targets are being evaluated, but B cell maturation antigen (BCMA) has proven to result in high response rates with excellent duration of responses in a very heavily pre-treated patient
- [3rd Annual Workshop on Genomics](https://www.myelomasociety.org/events/3rd-annual-genomics-meeting-genomics-and-translational-medicine-in-myeloma/) - Registration Rates In Person Registration Admission to scientific sessions. Admission to breakfasts, lunches, and coffee breaks. Certificate of attendance. One-year access to on-demand session recordings. Access instructions will be provided within 3 weeks post-event. On-demand Registration One-year access to on-demand session recordings. Access instructions will be provided within 3 weeks post-event.
- [Educational Workshop Marrakech, Morocco](https://www.myelomasociety.org/events/educational-workshop-marrakech-morocco/) - The official language of the 2025 Marrakech Educational Workshop is English. Live translation to French will be provided on a complimentary basis to all in-person attendees. On-demand sessions will be available in both French and English. Registration Rates In Person Registration Admission to scientific sessions. Admission to breakfasts, lunches, and coffee breaks. Certificate of attendance. One-year access to on-demand
- [Newly Diagnosed Multiple Myeloma Webinar - West Coast](https://www.myelomasociety.org/events/newly-diagnosed-multiple-myeloma-webinar-west-coast/)
- [Newly Diagnosed Multiple Myeloma Webinar - East Coast](https://www.myelomasociety.org/events/newly-diagnosed-multiple-myeloma-webinar-east-coast/)
- [6th Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/events/6th-immune-effector-cell-therapies-in-multiple-myeloma-workshop/) - Registration Fees In Person Registration Admission to scientific sessions. Admission to breakfasts, lunches, and coffee breaks. Certificate of attendance. One-year access to on-demand session recordings. Access instructions will be provided within 3 weeks post-event. On-demand Registration One-year access to on-demand session recordings. Access instructions will be provided within 3 weeks post-event.
- [webIMarS - Australia](https://www.myelomasociety.org/events/webimars-australia/) - About webIMarS These 90-minute webinars on Relapsed Refractory Multiple Myeloma will be led by local faculty and designed for a regional audience. The goal of this series is to share updated knowledge in diagnosis, monitoring, and treatment of Plasma Cell malignancies with a focus on the local practice patterns.
- [webIMarS - Japan](https://www.myelomasociety.org/events/webimars-japan/) - About webIMarS These 90-minute webinars on Relapsed Refractory Multiple Myeloma will be led by local faculty and designed for a regional audience. The goal of this series is to share updated knowledge in diagnosis, monitoring, and treatment of Plasma Cell malignancies with a focus on the local practice patterns.
- [Educational Workshop Johannesburg, South Africa](https://www.myelomasociety.org/events/educational-workshop-johannesburg-south-africa/) - Program now available In Person Registration Admission to scientific sessions. Admission to breakfasts, lunches, and coffee breaks. Certificate of attendance. One-year access to on-demand session recordings. Access instructions will be provided 3 weeks post-event. On-demand Registration One-year access to on-demand session recordings. Access instructions will be provided within 3 weeks post-event.
- [Educational Workshop, Buenos Aires, Argentina](https://www.myelomasociety.org/events/educational-workshop-buenos-aires-argentina/) - Registration Rates In Person Registration Admission to scientific sessions. Admission to breakfasts, lunches, and coffee breaks. Certificate of attendance. One-year access to on-demand session recordings. Access instructions will be provided 3 weeks post-event. On-demand Registration One-year access to on-demand session recordings. Access instructions will be provided 3 weeks post-event.
- [WebIMarS Series: Relapsed Refractory MM](https://www.myelomasociety.org/events/webimars-series-rrmmin/)
- [Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma](https://www.myelomasociety.org/events/practical-insights-in-and-translational-aspects-of-novel-immune-therapies-in-multiple-myeloma/)
- [21st IMS Annual Meeting](https://www.myelomasociety.org/events/21st-ims-annual-meeting/) - About the Location Riocentro, a world-class meeting venue, situated in the heart of Rio de Janeiro, is easily accessible from the city center and major transportation hubs. This central location makes it convenient for attendees traveling from different parts of the city and internationally. The self-contained campus is secure and environmentally friendly. The IMS Annual
- [2nd Annual Genomics Meeting: Genomics and Translational Medicine in Myeloma](https://www.myelomasociety.org/events/2nd-annual-genomics-meeting/) - Tentative Agenda In Person Registration Admission to scientific sessions. Admission to breakfasts, lunches, and coffee breaks. Certificate of attendance. One-year access to on-demand session recordings. Access instructions will be provided 3 weeks post-event. On-demand Registration One-year access to on-demand session recordings. Access instructions will be provided within 3 weeks post-event.
- [5th Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/events/5th-immune-effector-cell-therapies-in-multiple-myeloma-workshop/) - Building upon the success of prior workshops, the International Myeloma Society is happy to host the 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop to discuss immune-based therapies in myeloma including the latest CAR T cell and bispecific T cell-engager clinical data, promising preclinical leads, updated correlative analyses exploring predictors of response and resistance mechanisms, and next-generation
- [Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar - West Coast](https://www.myelomasociety.org/events/practical-insights-in-novel-immune-therapies-in-multiple-myeloma-webinar-west-coast/) - The treatment of multiple myeloma has dramatically evolved in recent years with immune-based strategies resulting in a very high impact in the relapsed refractory setting. Several targets are being evaluated, but B cell maturation antigen (BCMA) has proven to result in high response rates with excellent duration of responses in a very heavily pretreated patient
- [Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar - East Coast](https://www.myelomasociety.org/events/practical-insights-in-novel-immune-therapies-in-multiple-myeloma-webinar-east-coast/) - The treatment of multiple myeloma has dramatically evolved in recent years with immune-based strategies resulting in a very high impact in the relapsed refractory setting. Several targets are being evaluated, but B cell maturation antigen (BCMA) has proven to result in high response rates with excellent duration of responses in a very heavily pretreated patient
- [FDA-IMS Joint Workshop: Defining Patient Populations for Clinical Studies in Multiple Myeloma](https://www.myelomasociety.org/events/fda-ims-joint-workshop-defining-patient-populations-for-clinical-trials-in-multiple-myeloma/)
- [Future of Drug Development in Multiple Myeloma: An IMS-FDA Joint Workshop](https://www.myelomasociety.org/events/future-of-drug-development-in-multiple-myeloma-an-ims-fda-joint-symposium/)
- [Practical Insights in Novel Immune Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/events/practical-insights-in-novel-immune-therapies-in-multiple-myeloma-workshop-3/) - Preliminary Program
- [4th Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/events/4th-immune-effector-cell-therapies-in-multiple-myeloma-workshop/) - Registration Rates Registration Category Virtual Rate Member $0.00 Non-Member $100.00 Non-Members in Training $50.00 Pharma Industry $150.00
- [Practical Insights in Novel Immune Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/events/practical-insights-in-novel-immune-therapies-in-multiple-myeloma-workshop-2/) - The treatment of multiple myeloma has dramatically evolved in recent years with immune-based strategies resulting in a very high impact in the relapsed refractory setting. Several targets are being evaluated, but B cell maturation antigen (BCMA) has proven to result in high response rates with excellent duration of responses in a very heavily pretreated patient
- [Practical Insights in Novel Immune Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/events/practical-insights-in-novel-immune-therapies-in-multiple-myeloma-workshop/) - The treatment of multiple myeloma has dramatically evolved in recent years with immune-based strategies resulting in a very high impact in the relapsed refractory setting. Several targets are being evaluated, but B cell maturation antigen (BCMA) has proven to result in high response rates with excellent duration of responses in a very heavily pretreated patient
- [19th International Myeloma Society Annual Meeting](https://www.myelomasociety.org/events/19th-international-myeloma-workshop/)
- [3rd Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/events/3rd-immune-effector-cell-therapies-in-multiple-myeloma-workshop/) - Registration rates Registration Category In Person Rate Virtual Rate Member $425.00 $0.00 Non-Member $525.00 $100.00 Non-Members in Training $100.00 $50.00 Pharma Industry $600.00 $150.00
- [IMS Novel Immune Therapies Educational Workshop Series](https://www.myelomasociety.org/events/ims-novel-immune-therapies-educational-workshop-series/) - More Information This high-impact, three-hour educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engagers, and CAR T therapies among healthcare professionals. At
- [18th IMW Virtual Platform](https://www.myelomasociety.org/events/18th-imw-virtual-platform/)
- [18th International Myeloma Workshop](https://www.myelomasociety.org/events/imw-vienna/) - IMW 2021 September 8-11, 2021 Vienna, Austria IMPORTANT COVID SAFETY UPDATE Updated 8/31/2021 IMPORTANT UPDATE: On August 30, 2021, the Council of the European Union adopted a non-binding Council Recommendation that may result in new travel restrictions for unvaccinated travelers from certain countries, including the United States. No new travel restrictions have been formally adopted by Austria
- [2nd Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/events/2nd-immune-effector-cell-therapy-in-multiple-myeloma-workshop/) - Building upon the success of the inaugural workshop held in April 2019, the International Myeloma Society is happy to host the 2nd Immune Effector Cell Therapy in Multiple Myeloma Workshop to discuss various immune-based therapies in myeloma including CART cell clinical data and promising preclinical leads, review the latest correlative analyses exploring predictors of response
- [IMS Educational Workshop](https://www.myelomasociety.org/events/ims-educational-workshop-2/)
- [IMS Educational Workshop](https://www.myelomasociety.org/events/ims-educational-workshop/)

## Officers

- [Katja Weisel, MD](https://www.myelomasociety.org/officers/katja-weisel-md/) - Katja Weisel, MD, is associate professor Deputy Head the Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg Germany as well as Co-Director of the German Cancer Aid designated University Cancer Center Hamburg (UCCH). Prof Weisel received her medical degree from the Medical School of the University
- [Natalia Paola Schütz, MD, MSc.](https://www.myelomasociety.org/officers/19271/) - Dr. Schütz is the Chief of the Hematology Department at Hospital Italiano de Buenos Aires, Argentina, and leads the Hematology Training Program at its affiliated medical school. A clinician and clinical investigator specializing in Multiple Myeloma and its precursor conditions, Dr. Schütz earned her medical degree from Universidad Favaloro and completed postgraduate training in Internal
- [Chandramouli Nagarajan MBBS, FRCP(Edin), FRCPath(UK)](https://www.myelomasociety.org/officers/chandramouli-nagarajan-mbbs-frcpedin-frcpathuk/) - Dr. Chandramouli is a Senior Consultant Haematologist at the Department of Haematology at Singapore General Hospital and National Cancer Center Singapore and the current Head of the SingHealth Duke NUS Blood Cancer Centre. He serves as the sub-Specialty Lead for Multiple Myeloma and Lymphoma in SGH and SingHealth-Duke NUS Blood Cancer Center. He has a
- [Suzanne Lentzsch, MD, PhD](https://www.myelomasociety.org/officers/suzanne-lentzsch-md-phd/) - Dr. Suzanne Lentzsch is Professor of Medicine and Director of the Multiple Myeloma and Amyloidosis Service at Columbia University. For over two decades, her clinical and translational research has focused on developing novel, patient-centered therapies for plasma cell disorders, particularly multiple myeloma and AL amyloidosis. Dr. Lentzsch's groundbreaking work led to the first-in-human trial of
- [Robert A. Kyle, MD](https://www.myelomasociety.org/officers/robert-a-kyle-md/) - Robert A. Kyle, MD is Professor of Medicine, Laboratory Medicine and Pathology at Mayo Clinic College of Medicine, in Rochester, Minnesota. He served as the Section Head and subsequently Chairman of the Division of Hematology. Dr Kyle is Chairman of the Scientific Advisory Board of the International Myeloma Foundation (IMF) and serves on the Board
- [María-Victoria Mateos, MD, PhD](https://www.myelomasociety.org/officers/maria-victoria-mateos-md-phd/) - María-Victoria Mateos, MD, PhD is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca’s University Hospital Haematology Department. She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in
- [Saad Z. Usmani, MD, MBA, FCAP](https://www.myelomasociety.org/officers/saad-z-usmani-md-mba-fcap/) - Dr. Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. He joined the Myeloma Institute for Research & Therapy,
- [Elena Zamagni MD, PhD](https://www.myelomasociety.org/officers/elena-zamagni-md-phd/) - Elena Zamagni MD, PhD, is an Associate Professor of Hematology at the Bologna University, Italy since January 2021. She received her medical degree from University of Bologna, where she also served her residency in haematology. She got PHD in Clinical Hematology at the University of Bologna in May 2005. She qualified for the position of
- [Noopur S. Raje, MD](https://www.myelomasociety.org/officers/noopur-s-raje-md/) - Dr. Raje is director of the Center for Multiple Myeloma and the Rita Kelley Chair in Oncology at the Massachusetts General Hospital Cancer Center at Harvard Medical School in Boston, MA. Her primary focus is treating patients with multiple myeloma and related plasma cell disorders. Dr. Raje leads a dedicated clinical team engaged in investigator-initiated,
- [Kenneth Anderson, MD](https://www.myelomasociety.org/officers/kenneth-anderson-md/) - Kenneth Anderson, MD is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. Over the last three
- [Shaji Kumar, MD](https://www.myelomasociety.org/officers/shaji-kumar-md/) - Shaji Kumar, MD is a consultant in the Division of Hematology at Mayo Clinic, and Professor of Medicine in the College of Medicine, Mayo Clinic, Rochester, MN. He is currently the Medical Director for the Cancer Center Clinical Trials Office. He also serves as the co-chair of the NCI Myeloma Steering Committee. Dr. Kumar’s research
- [Masahiro Abe, MD, PhD](https://www.myelomasociety.org/officers/masahiro-abe-md-phd/) - Dr. Abe is currently the President of Japanese Society of Myeloma (JSM), and a member of the Asian Myeloma Network (AMN) executive committee. He is also acting as an advisory doctor of Japanese myeloma patients’ society and a council member of Japanese Society of Bone and Mineral Research. He was a member of the local organizing committee
- [Jesús San Miguel, MD, PhD](https://www.myelomasociety.org/officers/jesus-san-miguel-md-phd/) - Jesús San Miguel, MD, PhD is a professor of medicine-hematology and director of clinical and translational medicine at the University of Navarra in Spain. He served as director of the Hematology Department of the University Hospital of Salamanca in Spain, for over 22 years (1991-2013). Dr San-Miguel has published over 700 original papers in international
- [Philippe Moreau, MD](https://www.myelomasociety.org/officers/philippe-moreau-md/) - Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France. He specializes in clinical hematology, with a particular focus on multiple myeloma and its treatment with high-dose therapy and novel agents. Dr Moreau was appointed University Professor of Clinical Hematology at Nantes Faculty of Medicine in 2003. Prof. Moreau
- [Nikhil C. Munshi, MD](https://www.myelomasociety.org/officers/nikhil-c-munshi-md/) - Nikhil C. Munshi, MD is Professor of Medicine at the Harvard Medical School and the Director of Basic and Correlative Science, and Associate Director of the Jerome Lipper Multiple Myeloma Center at the Dana Farber Cancer Institute and an attending physician at the Brigham and Women’s Hospital and the Boston VA Healthcare system, Harvard Medical

## Meeting Materials

- [22nd IMS Annual Meeting 2025](https://www.myelomasociety.org/meeting-materials/22nd-ims-annual-meeting-2025/) - Wednesday, September 17, 2025 OPENING CEREMONY Welcome Pioneers in Myeloma President’s Address Philippe Moreau KEYNOTE Co-chairs: Philippe Moreau and Keith Stewart Tumor-reactive γδ T cells Predict Responses to Antibody Drug Conjugates - Tak Mak CORE SESSION 1: PRECURSOR DISEASE Chair: Vincent Rajkumar, Co-chair: Maria-Victoria Mateos Genomic profiling - Mehmet Samur Microenvironment - Madhav Dhodapkar What
- [West Coast Webinar on NDMM and RRMM - April 2026](https://www.myelomasociety.org/meeting-materials/west-coast-webinar-on-ndmm-and-rrmm-april-2026/) - Introduction - Noopur Raje SMM and NDMM - Thomas Martin SMM Case Study - Surbhi Sidana NDMM Case Study - Anupama Kumar Panel Discussion All + Douglas Sborov Early Relapse and Choice of Immunotherapy - Amrita Krishnan Case Study - Rahul Banerjee
- [East Coast Webinar on NDMM and RRMM - April 2026](https://www.myelomasociety.org/meeting-materials/east-coast-webinar-on-ndmm-and-rrmm-april-2026/) - Introduction - Shaji Kumar SMM and NDMM - Nikhil Munshi SMM Case Study - Yuxin Liu NDMM Case Study Diana Cirstea Panel Discussion All + Suzanne Lentzsch Early Relapse and Choice of Immunotherapy- Saad Usmani Case Study - Gurbakhash Kaur
- [7th Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/meeting-materials/7th-immune-effector-cell-therapies-in-multiple-myeloma-workshop/) - Plenary Optimizing NK Cell Engineering for Therapeutic Efficacy - Katy Rezvani Session 1: Clinical Updates on CAR-T Cells Chairs: Jacob Laubach and Amrita Krishnan Ide-cel and Cilta-cel: Latest Updates and Ongoing Trials - Peter Voorhees Latest Real World Data for CAR T - Cells Doris Hansen Update on Anito-cel and GC012F - Matthew Frigault GPRC5D
- [Educational Workshop in Belgrade, Serbia](https://www.myelomasociety.org/meeting-materials/educational-workshop-in-belgrade-serbia/) - Plenary Talk From Biology to Therapy: The Current Landscape of Multiple Myeloma - Nikhil Munshi Session 1: Diagnosis, Risk Stratification, and Monitoring of Plasma Cell Disorders Co-chairs: Shaji Kumar and Jelena Bila Diagnostic Testing for Multiple Myeloma, Risk Stratification and Follow-up - Jelena Bila Update and Recommendations on Imaging Techniques in Myeloma - Elena Zamagni
- [ASH Meeting Materials 2025](https://www.myelomasociety.org/meeting-materials/ash-meeting-materials-2025/) - Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Genomics define neoplastic transformation in multiple myeloma precursor conditions Integrative genomic, single-cell, and functional profiling uncovers immune consequences of the CD48–CD244 axis in NK cells in multiple myeloma FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical
- [Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma - October 27, 2025](https://www.myelomasociety.org/meeting-materials/practical-insights-in-and-translational-aspects-of-novel-immune-therapies-in-multiple-myeloma-october-27-2025/) - Introduction Philippe Moreau and Hermann Einsele Advanced Diagnostics Chairs: Hartmut Goldschmidt, Annamaria Brioli, Cyrus Khandanpour Breakout Lesions/EMD - Niels Weinhold Single Cell Spatial Organization of Tumor Microenvironment- Leo Rasche Modulation of the Target Antigen - Florian Bassermann Monitoring for Infectious Post-T-Cell-Based Therapy - Heinz Ludwig Predictors of Response and Mechanisms of Relapse - Marc Raab
- [East Coast Webinar on RRMM - October 2025](https://www.myelomasociety.org/meeting-materials/east-coast-webinar-on-rrmm-october-2025/) - Intro to IMS and RR MM - Nikhil Munshi Treatment sequencing in RR MM - Saad Usmani Case Studies Early relapse - Zachary Avigan Late relapse with High Risk features - Ariel Siegel Panel discussion How I treat - Sundar Jagannath
- [West Coast Webinar on RRMM - October 2025](https://www.myelomasociety.org/meeting-materials/west-coast-webinar-on-rrmm-october-2025/) - Intro to IMS and RR MM - Noopur Raje Treatment sequencing in RR MM - Ajai Chari Case Studies Early relapse - Christen Dillard Late relapse with High Risk features - Bruno Almeida Costa Panel discussion How I treat - Robert Orlowski
- [Educational Workshop in Marrakech, Morocco](https://www.myelomasociety.org/meeting-materials/educational-workshop-in-marrakech-morocco/) - Friday, June 27, 2025 Plenary Talk: Multiple Myeloma: A Cure is on the Horizon - Philippe Moreau Diagnosis, Risk Stratification, and Monitoring of Plasma Cell Disorders Co-chairs: Jesus San Miguel and Abdallah Madani Diagnostic testing for Multiple Myeloma, risk stratification and follow-up - Jesus San Miguel Update and Recommendations on Imaging Techniques in Myeloma -
- [3rd Annual Genomics Meeting](https://www.myelomasociety.org/meeting-materials/3rd-annual-genomics-meeting/) - Current Definition and Management of Precursor Conditions Chairs: Kenneth Anderson and Sagar Lonial The importance of risk-stratifying for precursor conditions: IMWG risk stratification model - Maria-Victoria Mateos How do current risk stratification perform in clinical trials and pitfalls - Shaji Kumar Dynamic models - Irene Ghobrial Immune microenvironment and risk of progression - Nikhil Munshi
- [Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma](https://www.myelomasociety.org/meeting-materials/practical-insights-in-and-translational-aspects-of-novel-immune-therapies-in-multiple-myeloma/) - ROLE OF IMMUNOTHERAPY IN MM Co-chairs: Hartmut Goldschmidt, Martin Gramatzki, and Shaji Kumar Frontline Therapy 2025 - Francesca Gay Role of Belamaf in the Future - Katja Weisel Targets to Immunotherapy: Proteomics to predict outcome and drug resistance- Jan Krönke Managing short-term TCE/CAR T cell toxicities – what did we learn? - Marc Raab Late
- [6th Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/meeting-materials/6th-immune-effector-cell-therapies-in-multiple-myeloma-workshop/) - SESSION 1: CLINICAL UPDATES ON CAR T CELLS Chairs: Pieter Sonneveld and Yi Lin Ide-cel and Cilta-cel: latest data and ongoing trials - Noopur Raje Real world data for BCMA CAR T cells - Surbhi Sidana Novel autologous BCMA CAR T cells: latest data and ongoing trials - Matthew Frigault Update on GPRC5D CAR T
- [Educational Workshop in Johannesburg, South Africa](https://www.myelomasociety.org/meeting-materials/educational-workshop-in-johannesburg-south-africa/) - Plenary Talk From Biology to Therapy: The Current Landscape of Multiple Myeloma - Kenneth Anderson DIAGNOSIS, RISK STRATIFICATION, AND MONITORING OF PLASMA CELL DISORDERS Chairs: Shaji Kumar and Sharlene Parasnath Diagnostic testing for Multiple Myeloma, risk stratification and follow-up - Shaji Kumar Update and Recommendations on Imaging Techniques in Myeloma - Elena Zamagni MRD testing in
- [East Coast Webinar on NDMM - April 2025](https://www.myelomasociety.org/meeting-materials/east-coast-webinar-on-ndmm-april-2025/) - Intro to IMS and Set the Stage for NDMM - Noopur Raje Newly Diagnosed Myeloma: Triplicates vs Quadruplets - Faith Davies Case Study 1: Fit Patient - Benjamin Puliafito Case Study 2: Frail Patient - Nisha Joseph Panel discussion - Faculty + Jacob Laubach How I Treat - Sagar Lonial Summary and conclusion
- [West Coast Webinar on NDMM - April 2025](https://www.myelomasociety.org/meeting-materials/west-coast-webinar-on-ndmm-april-2025/) - Intro to IMS and Set the Stage for NDMM - Nikhil Munshi Newly Diagnosed Myeloma: Triplicates vs Quadruplets - Amrita Krishnan Case Study 1: Fit Patient - Sarah Lee Case Study 2: Frail Patient - Diana Cirstea Panel discussion - Faculty + Paola Neri How I Treat - Thomas Martin Summary and conclusion
- [ASH Meeting Materials 2024](https://www.myelomasociety.org/meeting-materials/ash-meeting-materials-2024/) - Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma - Francesco Maura Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax - Marcella Kaddoura Increased Expression of the Sialyltransferase Gene ST3GAL1 Predicts Lack of
- [21st IMS Annual Meeting 2024](https://www.myelomasociety.org/meeting-materials/21st-ims-annual-meeting-2024/) - Wednesday, September 25, 2024 OPENING CEREMONY Welcome Pioneers in Myeloma President’s Address- Philippe Moreau KEYNOTE: AI in Multiple Myeloma: Recent Findings and Opportunities - Anant Madabhushi PRECURSOR DISEASE Chair: Sagar Lonial, Co-chair: Maria-Victoria Mateos Approaches to Risk Stratification in High Risk Myeloma - Irene Ghobrial What have we learnt from iSTOPMM? - Sigurdur Kristinsson Co-evolution
- [5th Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/meeting-materials/5th-immune-effector-cell-therapies-in-multiple-myeloma-workshop/) - Saturday, March 23, 2024 Introduction and Welcome - Nikhil Munshi, Hermann Einsele, and Adam Cohen Session 1: Clinical Updates on CAR T Cells - Jesus San Miguel and Yi Lin Ide-cel: latest data and ongoing trials - Paula Rodriguez-Otero Cilta-cel: latest data and ongoing trials - Jesus Berdeja Real world outcomes with CAR T cells
- [Educational Workshop Buenos Aires, Argentina - April 2024](https://www.myelomasociety.org/meeting-materials/educational-workshop-buenos-aires-argentina-april-2024/) - Plenary Talk From Biology to Therapy: The Current Landscape of Multiple Myeloma- Jesus San Miguel Diagnosis Risk Stratification and Monitoring Plasma Cell Disorders Chair: Jesus San Miguel Diagnostic Testing for Multiple Myeloma, Risk Stratification and Follow up- Marivi Mateos Update and Recommendations on Imaging Techniques in Myeloma - Dorotea Fantl MRD Testing in Multiple Myeloma
- [Practical Insights in Novel Immune Therapies in Multiple Myeloma Series](https://www.myelomasociety.org/meeting-materials/practical-insights-in-novel-immune-therapies-in-multiple-myeloma-series/) - From 2021-2024, the IMS hosted Practical Insights in Novel Immune Therapies in Multiple Myeloma, a free educational program with meetings held both in person and virtually. This series sought to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of
- [2024 IMS/FDA Workshop: Defining Patient Populations for Clinical Studies in Multiple Myeloma](https://www.myelomasociety.org/meeting-materials/2024-ims-fda-workshop-defining-patient-populations-for-clinical-studies-in-multiple-myeloma/) - Session 1: Welcome Nikhil Munshi, International Myeloma Society Workshop Co-Chair, Dana Farber Institute Bindu Kanapuru, FDA Workshop Co-Chair, U.S. Food and Drug Administration Session 2: Relapsed or Refractory Multiple Myeloma Moderator: Nikhil Munshi Relapsed or refractory multiple myeloma - Kenneth Anderson Regulatory Considerations for approval in RRMM - Andrea Baines Panel Discussion: Kenneth Anderson, Andrea
- [19th IMS Annual Meeting 2022 Meeting Materials](https://www.myelomasociety.org/meeting-materials/19th-ims-annual-meeting-2022-meeting-materials/) - IMS Annual Meeting 2022 Thursday, August 25 Meet the Expert Extramedullary plasmacytoma - Laura Rosiñol/Meral Beksac Plasma cell leukemia - Carlos Fernandez de Larrea/Merav Leiba Management of Monoclonal gammopathy of clinical significance - Rafat Abonour/Nelson Leung Management of LC Amyloidosis - Anita D’Souza/Sandy Wong Management of Waldenström’s Macroglobulinemia - Steven Treon/Prashant Kapoor Management of POEMS
- [ASH Meeting Materials 2023](https://www.myelomasociety.org/meeting-materials/ash-meeting-materials-2023/) - Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterization of the MM and the Tumor Microenvironment Spatial Dissection of the Bone Marrow Microenvironment in Multiple Myeloma By High Dimensional Multiplex Tissue Imaging - Marc-Andrea Baertsch, MD The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions - Fumou Sun The
- [20th IMS Annual Meeting 2023](https://www.myelomasociety.org/meeting-materials/20th-ims-annual-meeting-2023/) - Wednesday, September 27, 2023 President's Address- Nikhil Munshi Keynote Address - Peter Campbell Origin of MM Cells Chair: Nikhil Munshi, Co-Chair: Faith Davies Charting the genetic evolution in myeloma cell - Faith Davies Novel in vivo models of myeloma origin - Karin Vanderkerken Failure of immune surveillance and disease evolution- Madhav Dhodapkar Is there a
- [4th Immune Effector Cell Therapies in MM Workshop - 2023](https://www.myelomasociety.org/meeting-materials/4th-immune-effector-cell-therapies-in-mm-workshop-2023/) - Session 1: CLINICAL UPDATES ON CAR T CELLS Update on ide-cel and cilta-cel in late-line MM - Noopur Raje Real world outcomes with CAR T cells for MM - Doris Hansen Update on other autologous CAR T cells - Matthew Frigault Should we move CAR T cells to early relapse/front line - Tom Martin Session
- [IMS/FDA Workshop: Future of Drug Development in Multiple Myeloma](https://www.myelomasociety.org/meeting-materials/ims-fda-workshop-future-of-drug-development-in-multiple-myeloma/) - SESSION 1: WELCOME Nikhil Munshi Bindu Kanapuru S E S S I O N 2 : T R I A L D E S I G N C O N S I D E R A T I O N S F O R N O V E L T H E R A P
- [ASH Meeting Materials 2022](https://www.myelomasociety.org/meeting-materials/ash-meeting-materials-2022/) - Myeloma and Plasma Cell Dyscrasias Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study - Carmelo Carlo Stella Tracking the Earliest Genomic Events in Multiple Myeloma Life-History - Anthony Cirrincione, PhD A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and
- [3rd Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/meeting-materials/3rd-immune-effector-cell-therapies-in-multiple-myeloma-workshop/) - Plenary Talk: Next generation CAR designs - Michel Sadelain Session 1: Clinical Update on CAR T cells Update on ide-cel data- Nina Shah Update on cilta-cel data - Jesus Berdeja Update on other BCMA CAR T cell products - Krina Patel Session 2: Clinical updates on Bispecific Antibodies/T-cell engagers BCMA bispecifics part 1: Teclistamab, Elranatamab,
- [ASH Meeting Materials 2021](https://www.myelomasociety.org/meeting-materials/ash-meeting-materials-2021/) - Autologous Transplantation: Clinical and Epidemiological Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial - Luciano Costa Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial - Hartmut
- [2nd Immune Effector Cell Therapies in Multiple Myeloma Workshop](https://www.myelomasociety.org/meeting-materials/2nd-immune-effector-cell-therapies-in-multiple-myeloma-workshop/) - Download the PDF version of the speaker slides. Introduction How will CAR T and BsAb fit in MM treatment paradigm?- Kenneth Anderson Session 1: Update on BCMA CAR T Clinical Data Update on ide-cel - Nikhil Munshi Update on cilta-cel -Deepu Madduri Update on orva-cel - Sham Mailankody Update on CT053 - Shaji Kumar
- [North America Virtual Educational Workshop 2020](https://www.myelomasociety.org/meeting-materials/north-america-virtual-educational-workshop-2020/) - Download the PDF version of the speaker slides. Session 1: Diagnosis and Monitoring of Myeloma Patients https://player.vimeo.com/video/477601611 Special Lecture: State of the Art for Multiple Myeloma today - Jesus San Miguel Diagnostic testing for Multiple Myeloma, and follow-up - Vincent Rajkumar Update and Recommendations on Imaging Techniques in Myeloma - Jens Hillengass Role of MRD in multiple myeloma - Nikhil Munshi Infections and
- [Europe/Middle East Virtual Educational Workshop 2020](https://www.myelomasociety.org/meeting-materials/europe-middle-east-virtual-educational-workshop-2020/) - Download the PDF version of the speaker slides. Session 1 https://player.vimeo.com/video/443014741 Diagnostic testing for Multiple Myeloma, and follow-up - Suzanne Lentzsch Update and Recommendations on Imaging Techniques in Myeloma - Elena Zamagni Role of MRD in multiple myeloma - Nikhil Munshi Infections and Vaccination during COVID-19 pandemic - Heinz Ludwig Live Panel Discussion: Diagnosis and follow up of patients Moderator: Meral Beksac Case presenters: Veselina
- [Latin America Virtual Educational Workshop 2020](https://www.myelomasociety.org/meeting-materials/latin-america-virtual-educational-workshop-2020/) - Download the PDF version of the speaker slides. Session 1 https://player.vimeo.com/video/436169479 Molecular Diagnostic in Myeloma - Rafael Fonseca Diagnostic and Follow-up - Dorotea Fantl Imaging Techniques in Myeloma - Natalia Schütz MRD in Myeloma - Bruno Paiva Monoclonal Gammopathy of Clinical Significance - Joan Blade Session 2 https://player.vimeo.com/video/436184706 Management of Newly Diagnosed MM transplant eligible - Sergio Giralt How I treat newly diagnosed elderly patients? - Ruben Niesvizky
- [ASH Meeting Materials 2020](https://www.myelomasociety.org/meeting-materials/ash-meeting-materials-2020/) - Download the PDF version of the speaker slides. Clinical Allogeneic and Autologous Transplantation Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial - Stefania Oliva Clinical Autologous Transplantation A Prospective Phase 2 Study to Assess
- [ASH Meeting Materials 2019](https://www.myelomasociety.org/meeting-materials/ash-meeting-materials-2019/) - Download the PDF version of the speaker slides. Adapting Novel Techniques into Clinical Endpoints for PCD Challenges of Progression free Survival and Overall Survival Endpoints in Multiple Myeloma - Vera Suman, PhD Challenges in Myeloma Therapy: What to do with MRD testing in Myeloma - Elisabet Manasanch, M.D., M.H. Adoptive Immunotherapy Mechanisms and New Approaches New Approaches Targeting
- [IMW Meeting Materials 2019](https://www.myelomasociety.org/meeting-materials/imw-meeting-materials-2019/) - 2019 IMW Meeting Agenda Thursday Welcome Robert Kyle Introdcution - Ken Anderson History of IMW - Robert Kyle State of Art for Myeloma in 2019 - San Miguel Precursor Conditions J Fermand N Bolli M Dhodapkar V Rajkumar R Kyle M Mateos I Ghobrial Multiple Myeloma, Diagnosis and Management Diagnostic Criteria and Workup in 2019 - S Kumar How
- [ASH Meeting Materials 2018](https://www.myelomasociety.org/meeting-materials/ash-meeting-materials-2018/) - Download the PDF version of the speaker slides. Multiple Myeloma: Clinical Updates from the ASH Annual Meeting 2018 Evangelos Terpos Pathophysiology of Thrombosis: Cancer- and Children-Associated Thrombosis The HAS-RISC Score for Venous Thromboembolism (VTE) Risk Stratification in Newly Diagnosed Multiple Myeloma Patients Starting Immunomodulatory Drugs (IMID) - Ang Li, MD Predicting Risk of Venous Thromboembolism in Multiple Myeloma:
- [ASH Meeting Materials 2017](https://www.myelomasociety.org/meeting-materials/ash-meeting-materials-2017/) - Download the PDF version of the speaker slides. Multiple Myeloma: Clinical Updates from the ASH Annual Meeting 2017 Evangelos Terpos Berdeja, Jesus: Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: Updated results from a multicenter study of bb2121 anti-BCMA CAR T cell therapy Branagan, Andrew: Two Dose Series of High-Dose Influenza Vaccine Is Associated with
- [ASH Meeting Materials 2015-2016](https://www.myelomasociety.org/meeting-materials/ash-meeting-materials-2015-2016/) - 2016 ASH Meeting Materials Download the PDF version of the speaker slides. Amyloidosis Gertz-NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Final Results From a Phase 1/2 Study Liedtke-Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response Palladini-A Randomized

## Categories

- [Uncategorized](https://www.myelomasociety.org/category/uncategorized/)

## Project Status

- [Past Projects](https://www.myelomasociety.org/project-status/past-projects/)
- [On Going Research](https://www.myelomasociety.org/project-status/on-going-research/)

## Type of Award

- [Translational Research Award](https://www.myelomasociety.org/type-of-award/translational-research-award/)
- [Career Development Award](https://www.myelomasociety.org/type-of-award/career-development-award/)

## Officers Categories

- [Officers](https://www.myelomasociety.org/officers-categories/officers/)
- [Board of Directors](https://www.myelomasociety.org/officers-categories/board-of-directors/)